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ABSTRACT 
Elizabeth Marie Martin: The use of metabolomic profiling to elucidate mechanisms underlying 
arsenic-associated diabetes 
(Under the direction of Rebecca C. Fry) 
 
Arsenic is a naturally occurring metalloid that is associated with numerous health effects. 
More than 100 million individuals are exposed globally to high levels of arsenic chronically 
through contaminated drinking water sources. Studies have shown these individuals are more 
likely to develop Diabetes Mellitus (DM). At present, the National Toxicology Program has 
classified chronic exposure to arsenic above 150 µg/L as a probable diabtogen. Furthermore, 
more recent epidemiological studies have highlighted that chronic arsenic exposure above 150 
µg/L maybe associated with DM. While in vitro and in vivo studies have elucidated possible 
mechanisms by which arsenic induces diabetes, it is still unclear which of these mechanisms is 
fully relevant to humans. Metabolomic profiling could help provide key insights into metabolic 
alterations that occur in individuals exposed to arsenic that lead to diabetes. As metabolomics is 
an emerging field profiling both diabetic and non-diabetic individuals chronically exposed to 
arsenic could provide insight into metabolic alterations associated with chronic arsenic exposure, 
as well as insight into which of these alterations are associated with the development of diabetes.  
The goal of this research was to identify metabolites associated with alterations in 
associated with arsenic exposure in diabetic and non-diabetic individuals in Chihuahua, Mexico. 
Using 492 unique metabolites in urine and plasma through an untargeted metabolomic screening, 
we assessed the relationship between these metabolites total urinary arsenic (U-tAs), a 
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commonly used measure of arsenic exposure, arsenic metabolism, as measured through speciated 
urinary arsenicals, and genotype of Arsenic +3 oxidation state methyltransferase (AS3MT), the 
main enzyme responsible for arsenic metabolism. We demonstrated that the identified 
metabolites are associated with alterations of key metabolic pathways including glucose 
metabolism, amino acid metabolism and vitamin B metabolism in association with arsenic 
exposure, arsenic metabolism and genotype of AS3MT in both diabetic and non-diabetic subjects. 
Many of the identified metabolites are associated with enzymes and metabolic pathways 
associated with the development of diabetes. Taken together, our research increase knowledge of 
mechanistic associations between arsenic-associated diabetes in humans.  
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INTRODUCTION 
 Type 2 Diabetes Mellitus (DM) is a metabolic disorder characterized by disruption of the 
insulin signaling pathway resulting in insulin resistance and pancreatic β-cell dysfunction and in 
limited uptake of glucose by cells. More than 641 million people are affected by type 2 diabetes 
globally, with between 17% and 40% unexplained by rises in obesity and other associated 
lifestyle factors [1]. Numerous studies have investigated the role of environmental contaminants 
in the development of diabetes [2, 3]. Of the chemicals investigated, the 2011 National 
Toxicology Program Workshop on diabetes and the Environment found sufficient evidence for 
the relationship between exposure to moderate and high (> 150 µg iAs/L) levels of inorganic 
arsenic in drinking water and diabetes [4]. At the time, the Workshop deemed the evidence for 
association between moderate to low level (< 150 µg iAs/L) exposure to be insufficient [4].  
Globally, more than 200 million people are exposed to inorganic arsenic at levels that 
exceed 10 µg As/L [5].  Of the numerous health effects associated with arsenic, including cancer 
of the skin and bladder, cardiovascular disease, stroke neurological effects and peripheral 
vascular disease [6], diabetes has been long studied, with several plausible mechanisms 
suggested by in vivo and in vitro laboratory studies [6, 7]. Such in vitro and in vivo studies have 
evaluated the impacts of arsenic on processes that govern glucose homeostasis, supporting that 
arsenic impairs insulin-dependent glucose uptake by inhibiting insulin-activated signal 
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transduction pathway, upregulates gluconeogenesis, and inhibits glucose-stimulated 
insulin secretion by pancreas [8].   
The combined studies in this work investigate the mechanistic relationship between 
arsenic exposure and diabetes development through metabolomics profiling of humans, both 
diabetic and non-diabetic individuals, exposed to arsenic. These studies represent some of the 
first to assess alteration in the metabolome in relationship to arsenic exposure. The ultimate goal 
of these studies is to increase current knowledge surround mechanistic relationships by which 
arsenic may induce diabetes in humans, thus acting as a foundation for future research efforts in 
pinpointing the mechanism, development of therapeutic targets, and preventative strategies for 
arsenic-induced diabetes.  
i. Sources of Arsenic Exposure 
 Arsenic is a naturally occurring inorganic metalloid that is ubiquitous across the globe. 
Humans are typically exposed through ingestion and inhalation. Dermal contact is a potential 
source of exposure as well however, very little is regarding how arsenic may enter the body 
through contact with the dermis, and health effects have only been reported in isolated 
occupational incidents. Inhalation exposure typically occurs in an occupational setting. However, 
it is also a component in tobacco smoke. More typically for the general population, ingestion is 
the primary route of exposure.  
Arsenic is found in food stuffs and drinking water. Food stuffs commonly containing 
arsenic include seafood, and rice. Fish and shellfish are often the primary source of arsenic 
exposure in populations with low levels of arsenic in drinking water. However, arsenic found in 
seafood is predominately converted to arseno-betaine, a non-toxic arseno-sugar that is not linked 
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to detrimental health effects. In addition to seafood, arsenic has more recently been detected in 
other food stuffs. These include kale, wine, rice and chocolate. It is unclear what the health 
impacts of consumption of arsenic from these foods are as arsenic is present in metabolites 
different from those found in fish. Rice consumption is presently an area of active research as it 
is a staple crop for a large portion of the global population. Research efforts in this area have 
focused on breeding rice to take up less arsenic as well as irrigating crops with uncontaminated 
water. The health impacts of arsenic exposure through food is an active area of research.  
 Drinking water arsenic, primarily found in wells that are contaminated by natural sources 
like bedrock is the primary source of global arsenic toxicity. More than 100 million individuals 
are exposed above the WHO/USEPA limit of 10 µg/L globally. The most notable example of a 
large population exposed to high levels of arsenic from wells is East Bengal and Bangladesh, 
where approximately 20 million individuals are exposed above the Bangladesh MCL of 50 µg/L. 
Other countries, such as Mexico, Argentina, Twain and Thailand also have large populations 
experiencing high levels of arsenic due to contaminated drinking water. Furthermore, there are 
examples of exposure to arsenic in the United States for individuals who use private wells as 
drinking water sources. Given the range of exposure and large number of people exposure to 
arsenic, understanding arsenic toxicity and arsenic-induced disease is a global public health 
concern.  
ii. Population-based studies of arsenic-associated diabetes mellitus 
Population-based studies of arsenic-associated diabetes can typically be grouped into two 
study types: those examining the impacts of low exposure (<150 µg iAs/L), those examining the 
impacts of high exposure (>150 µg iAs/L) as defined by the NTP workshop [4]. To date, studies 
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at high exposure levels provide the most consistent results, typically finding a positive 
association between arsenic and DM. The studies of lower levels of exposure and occupational 
exposure report inconsistent results.  
a. Studies of arsenic-associated diabetes at high levels of exposure (DW-iAs > 150 
µg/L) 
A study of high levels of exposure in Taiwan was the first to identify the association 
between arsenic and diabetes [9]. Since then, there have been nine studies of exposures at high 
levels with three occurring in Bangladesh [10-12], five occurring in Taiwan [13-17], and one 
taking place in Cambodia [18] (Supplemental Table 1). Of all ten studies, seven have found 
associations between arsenic and diabetes in males and females [9, 11-16, 19], and one found 
associations between arsenic and diabetes in females [17]. Two studies found no association 
between arsenic and diabetes [10, 18] (Supplemental Table 1). These studies are difficult to 
compare directly as they did not use a common metric for diabetes diagnosis or arsenic exposure. 
Additionally, each study adjusted for different covariates. Arsenic exposure measures used were 
the cumulative exposure index (CEI) (n=5), direct drinking water measures (DW-iAs) (n=4), 
endemic vs. non-endemic regions (n=2), and the presence or absence of keratosis (skin lesions) 
(n=1) (Table 1). diabetes metrics used were self-reported (n=3), oral glucose tolerance testing 
(OGTT) (n=4), blood glucose levels, (n=4), glycosuria (n=2), HbA1c measurements (n=1), 
treatment history (n=1), death certificates (n=1) and insurance claims (n=1) (Supplemental Table 
1). In terms of adjustment factors, two studies conducted were completely unadjusted [17, 18]. 
The remainder typically adjusted for age, sex, and/or BMI, with only two studies including 
additional factors of smoking status and education and physical activity (Supplemental Table 1). 
When considering the two studies that did not identify an association between arsenic and DM, 
Chen et al had a relatively small number of cases (n=241), despite the large size of the cohort 
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(n=11,319) [10], and the Huang et al study was a relatively small study (n=142 total) making it 
potentially underpowered [18]. While there has been some criticism of the eight studies that have 
detected an association [20, 21], they were all well powered, and include a prospective cohort 
study [14, 15]. Thus, overall, these studies suggest that arsenic and diabetes are linked 
b. Studies of arsenic-associated diabetes at low levels of exposure (DW-iAs < 150 µg /L) 
 A total of 38 human population based studies have been conducted at lower levels of 
arsenic exposure (DW-iAs <150 µg/L). Of these studies 27 have found an association between 
arsenic levels and DM, and 11 have found no association between arsenic and diabetes 
(Supplemental Table 1). Unlike studies of high exposure that have taken place in a limited 
number of regions. Studies of lower exposures have occurred in Bangladesh [22, 23], Canada 
[24, 25], China [26-29], Cyprus [30], Denmark [31], Iran [32], Italy [33], Mexico [34-37], Serbia 
[38], South Korea [39-41], Spain [42], Taiwan [43], the United Kingdom [44] and the United 
States of America [45-58]. Similar to the studies of high exposures, different metrics of arsenic 
exposure, diabetes and adjustment factors were used. Arsenic exposure was determined by U-tAs 
for 15 studies, DW-iAs for eight studies, blood arsenic for three studies, CEI for three studies, 
geographic region based arsenic measures for three study, hair arsenic for two studies, time 
weighed average exposures for 2 studies and, exfoliated urothelial cells for one study.  For 
determination of DM, the majority of studies (n=26) used either a biomarker measure (FBG > 
126, 2HBG > 200, HbA1c > 6.5, Oral Glucose Tolerance Test), whether a subjected used 
diabetes medication or physician diagnosis. The remaining studies used 12 studies used a variety 
of metrics, including death certificates and mortality registries (n=4), hospital/physician records 
(n=3), only self-reporting (n=2), national registries (n=1), and two studies did not report how 
they collected information on diabetes status. Importantly, two studies identified associations 
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between arsenic and gestational diabetes [25, 46], as opposed to the remainder of studies that 
examined adult onset DM. In addition to these studies of gestational diabetes, there has been an 
additional study that has shown that women that develop gestational diabetes have a higher level 
of U-tAs than their non-diabetic counterparts [59]. As before, these studies used a variety of 
adjustment factors, with age, sex and/or BMI being common (Supplemental Table 1). 
Additionally, these studies tended to consider the impact of race, creatinine, smoking status, and 
alcohol consumption more often than studies at higher exposure levels (Supplemental Table 1). 
Studies at the lower end of arsenic exposure tended to have mixed results, with significant 
attention being paid to adjustment factors [60-62]. For example, some studies which analyzed the 
same dataset and found opposing results depending on what covariates have been used [52, 53, 
55, 58].  Creatinine has been shown to be higher in diabetics as compared to their non-diabetic 
counter parts,  and thus adjustment of U-tAs would result in an overestimate of  arsenic exposure 
in diabetic individuals [63]. While the association between arsenic and diabetes is much less 
clear at lower exposures, the majority (n=25, 73.5%) of these studies did identify an association.  
At a lower level of exposure, studies have also looked at the impact of arsenic 
metabolism on the development of DM. Studies have shown that individuals with diabetes tend 
to have higher levels of U-tAs than their non-diabetic counterparts [59, 64-67]. Interestingly, 
both studies of blood arsenic levels have shown no difference between diabetic and non-diabetic 
individuals [67, 68]. This is likely because arsenic is cleared from blood within 4 hours, and thus 
represents a very immediate exposure to arsenic and not a chronic body burden. Additionally, it 
has been shown that individuals with diabetes have a different metabolomics profile than their 
non-diabetic counterparts exposed to arsenic, suggesting that numerous metabolic processes in 
addition to arsenic metabolism differ between these two groups [69].  These data clearly 
7 
 
represent an area of research that should be further explored. Additionally, as the only two 
prospective cohort studies, which could provide evidence for a causal link between arsenic and 
diabetes, have been conducted to date, there is a need for better study designs. 
In pooling the conclusions from these studies, two meta-analyses have been determined 
there is an association between chronic arsenic exposure at levels < 150µg iAs/L and diabetes 
[70, 71]. These meta-analyses found pooled relative risks of developing diabetes in the presence 
of arsenic equal to 1.7 and 1.23, respectively [70, 71].  Additionally, some studies in arsenic-
exposed human populations where arsenic is associated with biomarkers of pathological 
processes typically associated with DM. Specifically these biomarkers represent renal damage, 
oxidation stress, low-grade inflammation, and endothelial damage [72]. However, at present it is 
unclear what mechanisms are most relevant to the development of arsenic-associated diabetes in 
human populations. There is a gap in the knowledge regarding how arsenic’s induction of 
diabetes occurs in human population. Elucidating these mechanisms could be key for the 
development of effective intervention strategies and clinical treatment of the disease.  
iii. Mechanisms of arsenic-associated diabetes 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia 
that results from disruption of key processes involved in the regulation of glucose homeostasis. 
The sustained hyperglycemia is the result of the failure to produce or secret insulin in the 
pancreatic β-cells and/or the failure of peripheral tissues to respond to insulin signaling. Type 1 
diabetes is the result of an autoimmune condition where pancreatic β-cells are destroyed 
resulting in a loss of insulin and the subsequent inability of tissues to utilize blood glucose. In 
contrast, type 2 diabetes is characterized by impaired insulin signaling in peripheral tissues, i.e., 
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insulin resistance, and subsequent β-cell dysfunction.  Both type 1 and 2 diabetes are 
characterized by hyperglycemia. Interestingly, it has been demonstrated that laboratory animals 
exposed to inorganic arsenic develop phenotypes consistent with DM, namely increased fasting 
blood glucose, impaired glucose tolerance and/or insulin resistance [73-79]. Additionally, 
prenatal exposure to inorganic arsenic predisposes offspring to the development of diabetes in 
laboratory studies [80, 81]. In eleven of the thirteen currently published rodent studies, the doses 
used to promote diabetes in laboratory animals were much higher than those typically associated 
with the environmental exposures. It is important to note that these higher doses may be 
necessary as mice are less susceptible to arsenic-induced health effects than humans due to more 
efficient metabolism and clearance [82].  
In vitro and in vivo laboratory studies support four major mechanisms by which inorganic 
arsenic and its methylated metabolites are able to influence DM-related processes (Table 1). The 
first mechanism is the inhibition of insulin signaling, resulting in insulin resistance and in an 
impaired glucose uptake and utilization. The second mechanism is the induction of apoptosis of 
pancreatic β-cells, the primary site of insulin synthesis. The third mechanism is the inhibition of 
glucose stimulated insulin secretion by pancreatic β-cells at non-cytotoxic concentrations. The 
fourth mechanism is induction of gluconeogenesis. While these processes are also involved in 
type 2 diabetes [79] the ability of arsenic to dysregulate these processes suggests it is a 
diabetogen.  
In addition to inorganic arsenic exposure, different methylated metabolites of arsenic 
influence processes involved in the development of diabetes to different degrees, suggesting that 
metabolism of arsenic is key to likelihood of diabetes development. While the majority of 
arsenic taken up into the body is inorganic arsenic, it is metabolized by the enzyme arsenic (+3-
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oxidation state) methyltransferase (AS3MT) to different forms. AS3MT, and to a lesser extent 
other enzymes first methylate and reduce inorganic arsenic to produce monomethyl arsenicals 
(MMAs3+, MMAs5+). This process is repeated to produce dimethyl arsenicals (DMAs3+, 
DMAs5+). Importantly, it has been shown that the trivalent arsenicals are much more potent that 
the pentavalent counterparts as inhibitors of insulin signaling and insulin secretion by β-cells, 
suggesting that the trivalent species may be the main drivers of arsenic-associated diabetes [83].  
However, it is important to note that limited evidence on pentavalent arsenical species hinders 
the ability to understand their roles in the induction of arsenic-associated DM. The use of 
biomarkers of cell injury and altered glucose signaling provides support that arsenic-induced 
injuries resulting in diabetes occur in humans. Taken together, the following studies of the effect 
of arsenic on glucose homeostasis pathways provide cohesive evidence that arsenic can cause the 
development of DM.  
Mechanism 1: arsenic inhibits insulin-dependent glucose uptake 
 Inhibition of GLUT4 localization to the plasma membrane 
 Inhibition of Akt signaling to mobilize GLUT4 
 Alterations of gene expression associated with Akt pathway 
 Upregulation of antioxidant pathways leading to decreased secondary messengers 
 Influence development of glucose transport system 
Mechanism 2: β-cell damage 
 Induction of apoptosis due to production of ROS 
 Induction of chronic inflammation due to production of ROS 
Mechanism 3: β-cell dysfunction 
 Failure to secrete insulin specifically in response to glucose in response to ROS 
Mechanism 4: stimulation of gluconeogenesis 
 Induces expression of phosphoenolpyruvate carboxykinase  
Table 1. Summary of major mechanisms underlying arsenic-associated diabetes 
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a. Mechanisms of arsenic-associated diabetes mellitus: inhibition of insulin-dependent 
glucose uptake (insulin resistance) 
Arsenic and its metabolites can alter glucose homeostasis by causing insulin resistance and 
impaired glucose uptake [82-84]. Arsenite (iAs3+), and its trivalent metabolites, methylarsonous 
acid (MMAs3+), and dimethylarsonous acid (DMAs3+), inhibits glucose transporter type 4 
(GLUT4) recruitment to the plasma membrane despite insulin stimulation in vitro [83] (Figure 
1). Further, in vitro studies have demonstrated that iAs3+  and MMAs3+ inhibit the insulin-
dependent activation of protein kinase B (Akt), a key signaling step required for GLUT4 
translocation to the plasma membrane, by preventing its phosphorylation by PDK-1 [77, 85] 
(Figure 1). DMAs3+ works downstream of Akt to prevent the recruitment of GLUT4, but the 
exact mechanism remains unclear (Figure 1). The process of Akt inhibition is compounded by 
the fact that arsenic can influence the expression of the PI3K transcription factor that is upstream 
of Atk, and that regulates other important steps in insulin signaling in vivo and in vitro [85, 86].  
 
Figure 1. Depiction of Mechanism 1 of arsenic associated diabetes. iAs3+ and its trivalent 
metabolites inhibit insulin-dependent glucose uptake by disrupting the insulin-activated signaling 
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cascade. iAs3+ and MMAs3+ have been shown to inhibit the phosphorylation of Akt by PDK, 
resulting in inhibition of GLUT4 translocation to plasma membrane; DMAs3+ inhibits signaling 
downstream of PDK/Akt, but the exact target has not been identified. Figure adapted from Paul 
et al. 2007 [77]. 
 Additionally, the expression of many of the genes in this pathway, including GLUT4, and 
Akt are decreased in response to arsenic exposure in vivo and in vitro [84, 86, 87].  In mice, 
arsenic exposure is associated with generation of reactive oxygen species (ROS) and 
upregulation of cellular antioxidant pathways including Nuclear factor erythroid 2-related factor 
2 (Nrf2) [88, 89]. The constitutive upregulation of Nrf2 and the consequent increase in 
antioxidant enzyme expression could inhibit insulin-stimulated glucose uptake as the insulin 
pathway may also require ROS as signaling molecules [87].  
In addition to directly inhibiting the process of insulin-dependent glucose uptake, arsenic 
can interfere with adipogenesis, the differentiation of pre-adipocytes to adipocytes, as well as  
differentiation of myoblast into myotubes in skeletal muscle at doses between 0.5 and 5 µM [84, 
90, 91]. Adipocytes in white adipose tissue and myotubes in skeletal muscle tissue play critical 
roles in glucose utilization and in the maintenance of blood glucose levels.  Arsenic inhibits 
adipocyte differentiation by altering the expression of key genes and transcription factors 
involved in adipogenesis, specifically peroxisome proliferator-activated receptor γ (PPAR-γ), and 
CCAAT/enhancer binding protein α (C/EBPα) [85, 90, 92, 93]. This indirectly affects numerous 
other proteins involved in adipocyte differentiation including p21 and A-FABP [94]. Alterations 
of adipogenesis likely lead to decreased lipid storage capacity and insulin resistance, as it has 
been shown that defects in adipogenesis are can result in insulin impairment and type two 
diabetes [90, 95].  
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It is also possible that arsenic influences the development of the insulin responsive 
glucose transport system [84], by decreasing the phosphorylation of mechanistic target of 
rapamycin (mTOR) and ribosomal protein S6 kinase B1 (p70), key regulators in this process 
[96]. Notably, in humans, urinary total arsenic (U-tAs) (a biomarker measure of arsenic 
exposure) is inversely associated with insulin sensitivity levels [97]. However, it has also been 
shown that arsenic exposure is inversely related to fasting plasma insulin and to the measure of 
insulin resistance (HOMA-IR) [36]. Similarly, mice that were exposed to arsenic and fed a high 
fat diet displayed impaired glucose tolerance and a dose-dependent decrease in HOMA-IR, likely 
due to lower fasting insulin and higher fasting blood glucose than in mice fed a low fat diet [79].  
Insulin response to glucose challenge was also impaired in these mice. Thus, both impaired 
insulin sensitivity and impaired insulin secretion in response to high blood glucose may underlie 
the diabetogenic effects of arsenic exposure.  
b. Mechanisms of arsenic-associated diabetes mellitus: β-cell damage 
 Arsenic can damage pancreatic β-cells. It has been shown that arsenic metabolites 
accumulate in the pancreases of mice exposed to arsenic [73, 78, 82]. Arsenic accumulation 
induces apoptosis of pancreatic β-cells in vitro, likely through the production of ROS, and 
induction of PARP and Caspase-3, as well as through other mechanisms [91, 98-100].  In 
addition to causing cell death, this accumulation of ROS has been shown to result in chronic 
inflammation. Such chronic inflammation can result in pancreatitis in vivo which can lead to the 
development of diabetes [100]. Moreover, excessive levels of ROS result in upregulation of 
antioxidant pathways. It has been proposed that a persistent activation of Nuclear factor 
(erythroid-derived 2)-like 2(Nrf2), a key transcription factor in the antioxidant system, reduces 
glucose-triggered ROS-mediated signaling and thus inhibits glucose-stimulated insulin secretion 
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in vitro [101]. Exposure to As3+ and MMAs3+ have also been shown to lead to  inhibition of 
thioredoxin reductase in vivo, a key member of the cellular anti-oxidant defense, thus resulting in 
apoptosis [73, 102].   
c. Mechanisms of arsenic-associated diabetes mellitus: β-cell dysfunction 
Arsenic and its methylated metabolites can inhibit insulin gene transcription and/or 
secretion in the pancreas. Some studies suggested that iAs3+ may decrease the levels of insulin 
mRNA produced by pancreatic β-cells. Decreased insulin mRNA production would produce the 
same effect as destruction of these cells, however there have been conflicting data on the subject, 
likely due to dose differences [103, 104]. The destruction of cells by ROS-mediated mechanisms, 
as well as other cellular targets of iAs3+, directly impacts the ability of the pancreases to produce 
insulin.  Recent in vitro research has demonstrated that exposure of pancreatic islets to low 
arsenic concentrations can produce insulin, but fail to secrete it results in a blunted glucose-
stimulated insulin secretion [103, 104]. Consistent with these findings are results of a recent 
population study that showed arsenic exposure to be associated with decrease in the insulin 
secretion index, HOMA2%B [41].  An additional in vitro study using a β-cell line suggested that 
this is likely due to As3+ ability to inhibit calcium oscillation which is necessary for glucose 
stimulated insulin secretion [105]. Interestingly, in vitro both MMAs3+  and DMAs3+  are more 
potent inhibitors of glucose-stimulated insulin secretion by pancreatic islets than iAs3+, though 
the mechanisms for this are unclear [104]. It has also been shown in vitro that the cellular 
adaptation to chronic oxidative stress caused by iAs3+  exposure lowers ROS production and 
impairs glucose-stimulated insulin secretion, which may require low level-ROS as one of the 
regulatory mechanisms [106].  
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d. Mechanisms of arsenic-associated diabetes mellitus:  stimulation of gluconeogenesis  
In addition to inhibiting insulin secretion, gene expression changes induced by arsenic in 
vivo can also induce hepatic gluconeogenesis. Hepatic gluconeogenesis is the pathway for 
synthesis of glucose from non-carbohydrate sources during fasting. Arsenic induces increased 
expression of phosphoenolpyruvate carboxykinase, a rate limiting enzyme in gluconeogenesis 
resulting in fasting hyperglycemia [107, 108]. In summary, these data provide potential 
mechanistic understanding of how arsenic is able to regulate glucose hemostasis resulting in 
hyperglycemia and DM.   
iv. Genetic underpinnings for arsenic-associated diabetes mellitus 
Inter-individual genetic differences have been associated with differential risk for 
arsenic-associated DM. Multiple studies have found that differences in the metabolism of 
inorganic arsenic and in the distribution and excretion of arsenic metabolites are associated with 
likelihood of diabetes development [37, 50, 109-111]. As detailed previously, inorganic arsenic 
(iAs) is methylated primarily by AS3MT to form the monomethylated and dimethylated arsenic 
metabolites, MMAs and DMAs.  Studies of arsenic-exposed populations have found that higher 
iAs and MMAs in urothelial cells and higher DMAs in urine, are more strongly associated with 
diabetes than drinking water measures of arsenic or urinary total arsenic [35, 36, 50, 66]. These 
differences in arsenic metabolite profiles represent a potential indicator of the risk of developing 
diabetes and could be mediated by differences in genotypes, specifically single nucleotide 
polymorphisms (SNPs), of critical genes such as: AS3MT [112], Calpain 10 (CAPN-10) – a 
calcium-dependent protease that plays a key role in exocytosis of insulin containing vesicles in 
βcells [113], Glutathione S-Transferase Omega 1 (GSTO1)- a enzyme that contributes to the 
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reduction of arsenic from the pentavalent to trivalent form [110], and Notch 2 (NOTCH2) a 
member of a signaling cascade involved in cell differentiation [110, 111, 113, 114]. Interestingly, 
the majority of SNPs associated with differences in arsenic metabolism occur in non-coding 
regions of the genes, suggesting potential epigenetic regulation of gene expression or splice 
variants.  
v. Metabolomics 
 Metabolomics is an untargeted screening of small molecule metabolites (i.e. products and 
substrates of metabolism). This can occur at the level of the cell, tissue, biological fluid or 
organism at a given point in time. The goal is to measure and identify as many metabolites as 
possible to understand the present of state of the biological system. Typically, mass spectrometry 
and NMR spectroscopy are the most comment techniques for metabolome profiling.  
Metabolomics can be applied to assess the relationship between metabolite levels and 
various stimuli to inform what key processes are being altered in a biological response. This 
technology has numerous applications including understanding alterations associated with 
chronic disease state, environmental exposure, drug development, or infection. Metabolomics 
has been applied to assess diabetes with a total of 22 targeted and untargeted metabolomics 
studies assessing metabolomics impacts of diabetes[115]. This work represents one of the first of 
its kind as it was among the first to assess metabolomic impacts of arsenic exposure in humans. 
Specifically, the 22 studies of metabolomics profiles related to diabetes have found increased 
levels of the plasma branch chain and aromatic amino acids, specifically isoleucine, leucine, 
valine, tyrosine and phenylalanine are associated with development of diabetes. These studies 
have found alterations in sugars (glucose, fructose, and inositol) and lipids (phospholipids, 
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sphingomyelins, triglycerides) are associated with diabetes as well as are predictive markers of 
diabetes development.  
vi. Project Approach 
 This research focuses on the use of metabolomics profiling to understand the response of 
diabetic and non-diabetic individuals to arsenic exposure. The central hypothesis of this 
research is arsenic-induced diabetes is different from traditional type 2 diabetes and that 
metabolomics profiles of arsenic exposed diabetics and non-diabetics can provide key 
insights into disease development risk and disease profile.  This project focuses on 
characterization of metabolomics profiles in response to arsenic exposure, measures of arsenic 
metabolism and genetic inter-individual differences related to arsenic metabolism. We assess 
metabolomics profiles across two matrices, urine and plasma, to understand the key metabolic 
pathways perturbed by arsenic that potentially lead to diabetes. It is notable that our research is 
the first to (1) assess metabolomics profiles in response to arsenic exposure in nominally healthy 
individuals (2) integrate metabolomics in an exposure X disease paradigm and (3) assess the 
relationship between metabolomics profiles and inter-individual differences related to toxicant 
metabolism and genetic variation.   
vii. Dissertation Organization 
 This dissertation is organized into three chapters. The first chapter describes the 
characterization of metabolites associated with urinary total arsenic in diabetic and non-diabetic 
individuals. The second chapter expands upon this to examine the role of arsenic metabolism on 
metabolite profiles in diabetic and non-diabetic individuals. The third chapter examines the 
relationship between genetic variation and metabolite profiles to understand genetic 
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susceptibility to arsenic-associated disease in a human population. Of particular interest these 
studies identify key pathway alterations unique to diabetic individuals exposed to arsenic. 
Additionally, we identify alterations in metabolites that have been previously associated with 
likelihood of development of diabetes. Finally, metabolic alterations associated with genotypic 
differences provide insight into differences related to inter-individual susceptibility to arsenic-
associated diabetes. These three studies provide insight into susceptibility and development of 
arsenic-associated diabetes.  
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CHAPTER 1: METABOLOMIC CHARACTERISTICS OF ARSENIC-ASSOCIATED 
DIABETES IN A PROSPECTIVE COHORT IN CHIHUAHUA, MEXICO 
 
1.1 Overview 
Drinking water contaminated with inorganic arsenic (iAs) is a major threat to human health 
with more than 100 million people worldwide exposed to levels that exceed the World Health 
Organization’s (WHO) recommended limit of 10 µg As/L [116]. Chronic exposure to arsenic has 
been linked to an increased risk of cancer and non-cancerous diseases, including cardiovascular 
disease and diabetes mellitus (DM) [117-121].  In vivo and in vitro studies arsenite (iAs3+) and 
its trivalent methylated metabolites inhibit insulin signaling, insulin-dependent glucose uptake, 
insulin secretion, and induce apoptosis in pancreatic β-cells [122].  Understanding which of these 
mechanisms contribute to the phenotype of arsenic-associated diabetes and mechanisms 
underlying this disease is essential for the development of effective treatment strategies in areas 
where drinking water is contaminated with arsenic.   
Given that metabolomics assessment allows for untargeted screening of a vast number of 
metabolites and allows for discovery of key pathways related to disease state and exposure we 
set out to utilize it in understanding the development of arsenic-associated diabetes. In the 
present work we chose to focus on urine and plasma metabolomics profiles as these represent 
easily obtainable bio-specimens. We measured 429 unique metabolites, 221 in plasma and 294 in 
urine, using LC-MS-TOF/GC-MS-TOF in 90 diabetic and 86 non-diabetic individuals. These 
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individuals came from a recently established a cohort of 1,165 Chihuahua residents exposed 
to a wide range of arsenic concentrations.  
A total of 132 metabolites were identified to shift in urine or plasma in response to arsenic 
exposure characterized by the sum of arsenic metabolites in urine (U-tAs).  While 33 metabolites 
were altered in both diabetic and non-diabetic subjects, diabetic individuals displayed a unique 
response to arsenic exposure with 59 altered metabolites. These metabolites were also different 
from metabolites associated with type 2 diabetes in previous research. The metabolites uniquely 
altered in response to arsenic exposure in diabetic individuals displayed enrichment of metabolic 
processes related to tricarboxylic acid cycle and amino acid metabolism.  
1.2 Study Objectives 
For this study, we set out to assess whether metabolomics profiles of arsenic-exposed non-
diabetic and-diabetic individuals were different. We tested this by comparing the metabolomics 
profiles of arsenic-exposed diabetic and non-diabetic individuals. Using Liquid 
Chromatography/Gas Chromatography coupled to Mass Spectroscopy, we assessed 426 unique 
urine and plasma metabolites. Using multivariable linear regression, we determined arsenic-
associated metabolites in diabetic and non-diabetic individuals. We then used pathway analysis 
to examine the context related to the changes we observed in metabolite alterations. Taken 
together this research suggests that diabetics exposed to arsenic develop a phenotype different 
from traditional type 2 diabetes.  
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1.3 Materials and Methods 
1.3.1  Study population 
All procedures involving human subjects were approved by the IRBs of UNC Chapel Hill 
and Cinvestav-IPN, and all participants signed a written consent.  A total of 1,165 adults (≥18 
years old) with a minimum of 5-year uninterrupted residency in Chihuahua, Mexico were 
recruited between 2008 and 2012 [123, 124].  Pregnant women and subjects reporting kidney or 
urinary tract infection were excluded because these conditions may affect profiles of arsenic 
metabolites in urine. Individuals with potential occupational exposure to arsenic (e.g., those 
working with pesticides or in mines or smelters) were also excluded.  Samples of drinking water 
were obtained from each subjects’ households.  An interviewer-administered study questionnaire 
was used to record data on residency, occupation, drinking water sources and use, smoking, 
alcohol consumption, and medical history.  Spot urine and fasting venous blood were collected 
during medical exams which included an oral glucose tolerance test with blood drawn 2 hours 
after a 75 g glucose dose.  Plasma from both fasting and two-hour blood samples and urines were 
immediately frozen and stored at -80oC.  Measures of body weight and height were obtained 
during the exams and used to calculate body mass index (BMI).   
The metabolomics analyses focused on a select set matched set of 90 diabetic and 90 
non-diabetic individuals. For comparison, 90 non-diabetic individuals were randomly selected 
from the cohort within strata of arsenic concentration in drinking water (<10, 10-49, 50-149, 
≥150 µg iAs/L), BMI (<25, 25-29, ≥30), sex and age (≤39, 40-49, 50-59, ≥60) to match the 
distribution of these factors among the cases.  The matching criteria were relaxed in four 
instances when there were no non-diabetic individuals in the same stratum as the case.  In 
addition, four non-diabetic subjects were subsequently excluded from the study because of 
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incorrect or missing data on arsenic in water, BMI or use of diabetic medication.  Thus, the final 
numbers of subjects included in the nested sub-cohort were 90 diabetic and 86 non-diabetic 
individuals. 
1.3.2 Diabetes determination 
Individuals were classified as diabetic if they had a fasting plasma glucose (FPG) ≥126 
mg/dL or two-hour blood glucose (2HPG) ≥200 mg/dL.  Individuals who reported previous 
diabetes diagnosis or use of diabetic medication but with both FPG <126 mg/dL and 2HPG <200 
mg/dL were not treated as diabetic individuals. Blood glucose levels, both fasting plasma 
glucose (FPG) and 2-hour plasma glucose (2HPG), were measured using a Prestige 24i 
Chemistry Analyzer (Tokyo Boeki, Tokyo, Japan).  The analyzer was calibrated to ensure 
accuracy prior to analysis with human sera containing both normal and elevated glucose levels 
(Serodos and Serodos PLUS, Human Diagnostics Worldwide). 
1.3.3 Arsenic assessment 
Hydride generation-atomic absorption spectrometry coupled with a cryotrap (HG-CT-
AAS) was used to determine the concentration of concentrations of arsenic species in urine: total 
iAs, total monomethyl-As (MMAs) and total dimethyl-As (DMAs)[125]. Metabolites were then 
summed together for the measure of urinary total arsenic (U-tAs). To ensure accuracy a certified 
standard reference material Arsenic Species in Frozen Human Urine (SRM 2669; National 
Institute of Standards and Technology) was analyzed with every single batch of urine samples 
shipped from the field to UNC. The concentrations of iAs species measured by HG-CT-AAS in 
SRM 2669 ranged from 86.7 to 106.4% of the certified values.  The limit of detection (LOD) for 
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arsenic in water was 0.1 µg iAs/L; LODs for iAs species in urine were 0.05 ng As/mL for 
MMAs or DMAs and 0.1 ng iAs/mL for iAs.   
1.3.4 Metabolomics assessment 
Metabolic profiling was carried out in plasma and urine using gas chromatography (GC) 
and liquid chromatography (LC) with time of flight-mass spectrometry (TOF-MS) detection 
[126-129].  Here, the GC-TOF-MS were obtained with electron impact ionization (70 eV) at full 
scan mode (m/z 40-600) with a Rxi-5ms capillary column (30 m × 250 µm i.d., 0.25-µm film 
thickness, Restek, PA, USA) on a Pegasus HT system (Leco Co., St Joseph, MI) coupled with an 
Agilent 6890 GC (Agilent Co., Santa Clara, CA), using helium as the carrier gas at a constant 
flow rate of 1.0 mL/min.  The acquired data files were analyzed by ChromaTOF software (Leco 
Co.).  The LC-TOF-MS mass spectra were obtained with Thean Agilent HPLC 1200 system 
coupled with 6220 MSD TOF-mass spectrometer (MS) (Agilent CorporationCo., Santa Clara, 
CA).  The acquired GC-TOF-MS and LC-TOF-MS data were processed using ChromaTOF 
software (Leco Co., St Joseph, MI),  Agilent MassHunter Qualitative Analysis Program 
(vB.05.00), and XCMS package (v1.24.1, http://metlin.scripps.edu) [130, 131]. Spectral data 
conversion was performed using the Agilent MassHunter Qualitative Analysis Program 
(vB.05.00) and XCMS package.  Metabolites were verified and annotated using an in-house 
library of >800 mammalian metabolites and the on-line databases, including the Human 
Metabolome Database (http://www.hmdb.ca/), the National Institute of Standards and 
Technology library, and the LECO/Fiehn Metabolomics Library.  Relative amounts of the 
metabolites (individual metabolite peak area divided by the sum of all metabolite peak areas) 
were used in statistical analyses.   
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1.3.5 Statistical Analyses 
Data were analyzed using the statistical packages SAS 9.3 (SAS Institute Inc., Cary, NC) and 
Partek® Genomics Suite TM Software (St. Louis, MO).  A Spearman rank test was used to 
quantify the relationship between DW-iAs and U-tAs.  Descriptive statistics were used to 
summarize iAs in drinking water, U-tAs, and other demographic factors.  Because specific 
gravity was found to be associated with diabetes status within this cohort [132] and urinary 
creatinine levels have been previously linked with arsenic exposure, unadjusted values of U-tAs 
were used in the primary model in the analyses [63, 133, 134]. The abundance levels of the 221 
plasma metabolites and 294 urine metabolites were used for analyses.  Human Metabolome 
Database Identifiers (HMDB IDs) were also determined for metabolites to facilitate comparison 
between other studies.  
The GC-TOF-MS and LC-TOF-MS analyses identified 294 urinary and 221 plasma 
metabolites, including 89 metabolites that were detected in both plasma and urine with a total of 
426 unique metabolites that were profiled in this study (Supp Table 1, Supp Table 2).  Multi-
variable regression models were used to establish relationships between metabolite levels and 
arsenic exposure in diabetic and non-diabetic individuals, where U-tAs was used as the main 
predictor variable and metabolite levels the dependent variable.  BMI, age and sex, were selected 
as covariates based on a priori association with diabetes.  Statistical significance was set at 
p<0.05, q<0.2.   
1.3.6 Enrichment Analyses 
Associations of statistically significantly metabolites with canonical metabolic pathways 
were determined using the MetPA tool within Metabolomics Pathway Analysis [135].  This tool 
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maps metabolites onto KEGG pathways and determines the statistical significance as well as the 
impact of metabolite groups. Human Metabolome Database (HMDB) identifiers were used for 
these analyses as they provided greater coverage of metabolites than did the metabolite names 
[135]. As the metabolites had already been statistically filtered, a more relaxed statistical 
significance of p<0.1 was used in the pathways analysis.  
1.4 Results 
1.4.1 Demographic description of the sub-cohort 
The sub-cohort selected for the present study (n = 176) consisted of 133 (75.6%) women 
and 43 (24.4%) men (Table 2). Men and women were equally represented in the diabetic and 
non-diabetic groups (Table 2).  There were no statistically significant differences on average 
between the two groups for BMI, age, drinking water iAs or U-tAs (Table 2).  Among the 176 
individuals, a total of 152 (86.9%) individuals were exposed to DW-iAs levels exceeding 25 µg 
iAs/L, the current maximum allowable contaminant value for iAs for drinking water supplies in 
Mexico. 
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 All Individuals 
 (n=176) 
Non-Diabetic Individuals 
(n=86) 
Diabetic Individuals  
(n=90) 
A. 
Demographics 
N (%) Mean (range) N (%) Mean (range) N (%) Mean (range) 
Sex       
Female 133 
(75.6%) 
- 65 
(75.6%) 
- 68 
(75.6%) 
- 
Male 43 
(24.4%) 
- 21 
(24.4%) 
- 22 
(24.4%) 
- 
Age (years) - 50  
(18-79) 
- 50  
(18-78) 
- 51  
(23-79) 
BMI - 30.4  
(18.3-45.2) 
- 30.1  
(19.2-43.6) 
- 30.7  
(18.3-45.2) 
Fasting Blood 
Glucose 
- 131.1  
(49.5-379.0) 
- 88.7  
(49.0.5-117)* 
- 169.7 
(63.0-379.0)* 
2-Hour Blood 
Glucose 
- 163.8 
(50.0-437.0) 
- 112.5 
(50.0-191.5)* 
- 211.1  
(50.5-437.0)* 
B. Arsenic 
Exposure  
N (%) Mean (range) N (%) Mean (range) N (%) Mean (range) 
DW-iAs 
(µg/L) 
- 68.4 
 (LOD-292.9) 
 65.8  
(LOD-284.7) 
 70.8  
(LOD-284.7) 
≤ 10 µg/L 20 
(11.3%) 
- 11 
(12.8%) 
- 9 
(10.0%) 
- 
≥ 10 µg/L 156 
(88.7%) 
- 75 
(87.2%) 
- 81 
(90.0%) 
- 
≤ 25 µg/L 24 
(13.1%) 
- 14 
(16.3%) 
- 10 
(11.1%) 
- 
≥ 25 µg/L 152 
(86.9%) 
- 72 
(83.7%) 
- 80 
(89.9%) 
- 
U-tAs1  - 86.8  
(3.85-348.6) 
- 80.5  
(6.11-348.61) 
- 92.6  
(3.85-346.3) 
Table 2. Demographic Characteristics of the Cohort that was metabolically profiled.  
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Only 20 water samples (11.3%) had DW-iAs below the WHO recommended value of 10 
µg iAs/L.  DW-iAs was significantly correlated with U-tAs: r = 0.37 p<0.01 (Figure 2).  The key 
characteristics of the entire Chihuahua cohort were described elsewhere [124, 132]. 
 
Figure 2. Correlation between urinary total arsenic (U-tAs) and drinking water arsenic (DW-
iAs) that demonstrates a correlation between the two measures of exposure. 
1.4.2 Characteristics of the metabolome  
Of the 426 unique metabolites measured, a total of 132 metabolites were significantly 
increased or decreased with exposure to arsenic (characterized by U-tAs) among either diabetic 
or non-diabetic individuals (Supplemental Table 2). Of these, 103 were urinary and 32 were 
plasma metabolites (Table 3), with three metabolites common to both urine and plasma 
(Supplemental Table 2).  However, the response to arsenic exposure differed between the 
matrices.  While in urine the concentrations for most of the altered metabolites (n=68, 66%) 
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increased, the concentrations of most of the plasma metabolites (n=20, 63%) decreased (Table 3, 
Supplemental Table 2).  
  Urine 
n (%) 
Plasma  
n (%) 
Overall 
n  
Overall 103 32 132 
Increased Metabolite Level 68 (66%) 9 (31%) 77 
Decreased Metabolite Level 35 (34%) 20 (68%) 55 
Non-diabetic Individuals 61 15 73 
Increased Metabolite Level 35 (57%) 3 (20%) 36 
Decreased Metabolite Level 26 (43%) 12 (80%) 37 
Diabetic Individuals 73 17 87 
Increased Metabolite Level 52 (71%) 9 (53%) 59 
Decreased Metabolite Level 21 (29%) 8 (47%) 28 
Table 3.  Number of U-tAs associated-metabolites in either plasma or urine. 
1.4.3 Metabolites associated with arsenic exposure in urine and plasma 
Of the 426 unique metabolites measured, a total of 132 metabolites were significantly 
increased or decreased with exposure to arsenic (characterized by U-tAs) among either diabetic 
or non-diabetic individuals (Supplemental Table 2). Of these, 103 were urinary and 32 were 
plasma metabolites (Table 3), with three metabolites common to both urine and plasma 
(Supplemental Table 2).  However, the response to arsenic exposure differed between the 
matrices.  While in urine the concentrations for most of the altered metabolites (n=68, 66%) 
increased, the concentrations of most of the plasma metabolites (n=20, 63%) decreased (Table 3, 
Supplemental Table 2). 
In urine, a total of 61 metabolites were associated with U-tAs among non-diabetic 
subjects and 73 metabolites were associated with U-tAs among diabetic subjects (Figure 3a, 
Table 3, Supplemental Table 2).  Of those metabolites, 30 were unique to non-diabetic 
individuals, 42 were unique to diabetic individuals, and 31 metabolites were associated with U-
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tAs in both groups (Figure 3a).  Among the 31 common metabolites were those related to amino 
acid metabolism, the tricarboxylic acid (TCA) cycle, and pyruvate metabolism.  The majority of 
the urinary metabolites showed a positive association with arsenic exposure: 35 of the 61 
metabolites in non-diabetics, and 52 of the 73 metabolites in diabetic individuals (Table 3, 
Supplemental Table 2).  
 
Figure 3. Comparison of plasma and urinary metabolites and pathways associated with arsenic 
exposure in diabetic and non-diabetic individuals. 
In plasma, a total of 15 metabolites were associated with U-tAs among non-diabetic 
individuals and 17 metabolites were associated with U-tAs among diabetic individuals (Figure 
3b, Supplemental Table 2).  No U-tAs-associated metabolites in plasma were common among 
the diabetic and non-diabetic subjects (Figure 3b, Supplemental Table 2).  Many of the plasma 
metabolites were negatively associated with arsenic exposure: 8 of the 17 metabolites in 
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diabetics and 12 of the 15 metabolites in non-diabetic individuals (Table 3, Supplemental Table 
2). Thus, across the two matrices diabetic individuals displayed altered levels of 59 metabolites 
(42 urinary metabolites and 17 plasma metabolites) (Supplemental Table 2).  
1.4.4 Identification of arsenic-associate diabetes finger print  
Using METPA to perform KEGG enrichment analysis, the 61 urinary metabolites 
associated with U-tAs in non-diabetic individuals were enriched for nine metabolic pathways 
(Figure 3c, Table 4).  Three of these pathways were associated with amino acid metabolism 
(alanine/aspartate/glutamate, phenylalanine, arginine and proline), five with carbohydrate/energy 
metabolism (TCA cycle, glyoxylate/dicarboxylate, galactose, pentose/glucoronate, and 
pyruvate), and one was associated with vitamin (riboflavin) metabolism (Table 4).   
The 73 urinary metabolites identified in diabetic individuals enriched for eight pathways 
(Figure 3c, Table 4).  Of these pathways, three were associated with amino acid metabolism 
(alanine/aspartate/glutamate, phenylalanine, taurine) and four with carbohydrate/energy 
metabolism (TCA cycle, glyoxylate, pentose and pyruvate).  One pathway was associated with 
nucleic acid (purine) metabolism (Table 4).   
When examining the overlap between the study groups at a pathway level, there were six 
pathways that were associated with U-tAs in both non-diabetic and diabetic subjects.  These 
were pathways for metabolism of alanine/aspartate/glutamate, glyoxylate/dicarboxylate, 
pentose/glucoronate, phenylalanine, and pyruvate, and TCA cycle (Figure 3c, Table 4).  Three 
pathways were unique to the metabolome of non-diabetic subjects, including the pathways of 
arginine/proline, galactose, and riboflavin metabolism. Two pathways involved in purine and 
taurine metabolism were unique to the metabolome of diabetic subjects. 
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When KEGG enrichment analysis was conducted for the 15 plasma metabolites 
associated with U-tAs in non-diabetic individuals, a single pathway was enriched, namely the 
pathway for biosynthesis of phenylalanine, tyrosine and tryptophan (Figure 3d, Table 4). The 17 
plasma metabolites associated with U-tAs in diabetic individuals enriched for eight pathways 
(Figure 3d, Table 4).  Of these eight, five are associated with amino acid metabolism 
(arginine/proline, lysine, phenylalanine, and tyrosine and aminoacyl-tRNA biosynthesis), two are 
associated with energy metabolism (nitrogen metabolism and TCA cycle), and one pathway is 
associated with thiamine metabolism (Table 4).   An examination of the overlap between the 
study groups at a pathway level revealed that there were no pathways associated with U-tAs in 
both non-diabetic and diabetic subjects (Figure 1d). Specifically, there was one pathway unique 
to the response of non-diabetic subjects to arsenic exposure, and eight pathways unique to the 
diabetic response to arsenic exposure.  
As a separate analysis, the 59 metabolites that were uniquely associated with U-tAs in 
diabetic individuals (i.e. 42 urinary metabolites and 17 plasma metabolites) were also assessed 
for their enriched metabolic pathways, a total of 10 metabolic pathways were identified (Table 
4). Among these, were 5 pathways related to amino acid metabolism, 3 related to energy 
metabolism and 2 related to B vitamin (biotin, riboflavin, thiamine) metabolism.    
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Class of 
Metabolism 
Metabolic 
Pathway 
Urine Urine Plasma Plasma Urine and Plasma 
  Non-Diabetic  
Individuals  
(n=61) 
Diabetic  
Individuals 
(n=73) 
Non-
Diabetic 
Individuals 
(n=15) 
 Diabetic  
Individuals 
(n=17) 
Diabetes Unique  
metabolites 
(n=59) 
Amino acid 
metabolism 
Alanine, aspartate 
and glutamate 
metabolism 
p=0.001 
Oxaloacetate (-),  
N-Acetyl-L-
aspartate(+), 
Aspartate (-), 
Glutamine (-) 
p=0.001 
N-Acetyl-L-
aspartate (+), 
Aspartate (-), 
Succinate(+) 
  
  
  
  
p=0.053 
Furmurate (+, P), 
succinate (+,U) 
Amino acid 
metabolism 
Aminoacyl-tRNA 
biosynthesis 
  
  
  
  
  
  
p<0.001 
 Glycine (+), 
Lysine (-), 
Tyrosine(-), 
Proline(+) 
p<0.001 
Glycine (+, P), 
Serine (+, U), 
Methionine(+, U), 
Lysine (-, P), 
Proline (+, P) 
Amino acid 
metabolism 
Arginine and 
proline 
metabolism 
p=0.061 
Glutamine (-), 
Guanidinoacetate 
(-), Creatinine (+),  
Pyrrole-2-
carboxylate (-) 
  
  
  
  
p=0.004 
Fumarate (+), 
Citrulline (-), 
Proline (+) 
 
Amino acid 
metabolism 
Glycine, Serine, 
Threonine 
Metabolism 
    p=0.039 
Serine(+, U), 
Glycine (+, P), 5-
Aminolevulinic 
acid(-, U) 
Amino acid 
metabolism 
Lysine 
Degradation 
  
  
  
  
  
  
p=0.01835 
Glycine (+), 
Lysine (-) 
p=0.006 
Glutaric acid (+, U), 
Lysine (-, P), 
glycine (+, P), 
Carnitine (-, U) 
Amino acid 
metabolism 
Phenylalanine, 
tyrosine and 
tryptophan 
biosynthesis 
  
  
  
  
p=0.086414 
Erythrose 4-
phosphate (-
) 
  
Amino acid 
metabolism 
Phenylalanine 
metabolism 
p=0.056 
Pheynlpurvate (-), 
Acetamide (-),  
4-Hydrobenzoate 
(-) 
p=0.010 
Phenylpyruvate 
(-), Acetamide (-
),  
Succinate (+) 
  
  
p=0.017 
Tyrosine (-), 
Fumarate (+) 
p=0.005 
Tyrosine (-, P), 
Phenylglyoxylic 
acid (+, U), 
Fumarate (+, P), 
succinate (+, P) 
Amino Acid 
Metabolism 
Taurine and 
hypotaurine 
metabolism 
  
  
p=0.055 
Acetylphosphate 
(-), Taurine (-) 
  
  
  
  
 
Amino acid 
metabolism 
Tyrosine 
Metabolism 
  
  
  
  
  
  
p=0.045 
Tyrosine (-), 
Fumarate (+) 
 
Energy 
metabolism 
Citrate cycle 
(TCA cycle) 
p<0.001 
Malate (+), 
Oxaloacetate (-), 
Aconitate (+), 
Isocitrate (+) 
p=0.006 
Malate (+), 
Succinate (+), 
Aconitate (+) 
  p=0.003 
Malate (+), 
Fumarate(+) 
P=0.039 
Furmarate (+, P), 
Succinate (+, U) 
Energy 
metabolism 
Galactose 
metabolism 
p=0.044 
Glyceraldehyde 3-
phosphate (-), 
Galactitol (+),  
Sucrose (+) 
       
Energy 
metabolism 
Glyoxylate and 
dicarboxylate 
metabolism 
p=0.015 
Oxaloacetate (-), 
Aconitate (+), 
Malate (+), 
Isocitrate(+) 
p=0.014 
Oxalate (-), 
Malate (+), 
Aconitate (+),  
Succinate (+) 
     
Energy 
metabolism 
Methane 
Metabolism 
    p=0.099 
Serine (+, U), 
glycine (+, P) 
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Energy 
metabolism 
Nitrogen 
Metabolism 
      p=0.012 
Tyrosine (-), 
Glycine (+) 
p=0.02 
Tyrosine (-, P), 
Taurine (-, U), 
Glycine (+, U) 
Energy 
metabolism 
Pentose and 
glucuronate 
interconversions 
p=0.019 
Glucaric Acid (+), 
Ribitol (+),  
Arabitol (+), 
Glyceraldehyde 3-
phosphate (-) 
p=0.079 
Glutaric Acid 
(+), Ribitol (+), 
Arabitol (-) 
      
Energy 
metabolism 
Pyruvate 
metabolism 
p=0.023 
Acetylphosphate ( 
-), Oxaloacetate (-
), Malate (+) 
p=0.022 
Homocitrate (+), 
Acetylphosphate 
(-), Malate (+) 
     
Nucleic 
Acid 
Metabolism 
Purine 
metabolism 
  p=0.096 
Adenosine (+), 
Aconitate (+), 
Oxalate (-), 
Cyclic AMP (+) 
     
Vitamin 
Metabolism 
Biotin 
Metabolism 
    p=0.012 
Biotin (+, U), 
Lysine (-, P) 
Vitamin 
metabolism 
Riboflavin 
metabolism 
p=0.062 
 Ribitol (+), 
Hydroquinone (+) 
       
Vitamin 
metabolism 
Thiamine 
metabolism 
      p=0.005 
Tyrosine (-), 
Glycine(+) 
p=0.054 
Tyrosine (-, P),  
Glycine(+, P) 
Table 4. Pathways enriched for U-tAs associated metabolites in plasma (P) and urine (U) of 
diabetic and non-diabetic individuals. Increases or decreases in metabolite levels are indicated 
with (+) or (-).  
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1.5 Discussion 
A consensus exists that moderate-to-high chronic exposures to arsenic are associated with an 
increased risk of diabetes [118].  However, questions remain about pathophysiological processes 
that underlie this disease and about the phenotype of diabetes developed in the presence of 
arsenic exposure.  One way of answering these questions is the identification of metabolic shifts 
associated with arsenic exposure among diabetic and non-diabetic individuals. Here we 
examined plasma and urine metabolites that were altered in response to arsenic exposure in both 
non-diabetic and diabetic individuals in our Chihuahua cohort where the association between 
arsenic exposure and prevalent diabetes was recently established [123, 124, 132]. These 
metabolites and their corresponding pathways were then compared to identify features that were 
common or unique to the non-diabetic and diabetic individuals in their response to arsenic 
exposure, to gain insight into arsenic-associated disease.   
We identified a total of 132 urinary and plasma metabolites that were associated with U-
tAs in either non-diabetic or diabetic individuals, with 103 urinary metabolites and 32 plasma 
metabolites. Approximately one third of the urinary metabolites that were U-tAs associated 
(31/103, 30%) were identified as common to both non-diabetic and diabetic subjects. It was 
interesting to note that in contrast to urine, no overlap was observed in plasma, highlighting the 
non-concordant results in the matrices measured. The 31 overlapping urinary metabolites include 
but are not limited to metabolites that broadly play a role in amino acid metabolism (aspartic 
acid), the TCA cycle (malate, cAMP) and pyruvate metabolism (acetylphosphate). It is important 
to note that all of these metabolites were changed similarly in their levels between non-diabetic 
and diabetic subjects demonstrating a broad, disease-independent response to arsenic exposure. 
As these pathways are critical for energy processing, including adenosine triphosphate (ATP) 
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production [136], alterations of these pathways could indicate impacts of arsenic exposure on 
cellular energy production.  In addition, the data suggest that effects of arsenic exposure within 
the shared pathways may differ between diabetic and non-diabetic subjects.  For example, the 
effects on TCA cycle in diabetics included shifts in succinate and fumarate while isocitrate and 
oxaloacetate were shifted only among non-diabetics; shifts in the concentrations of another two 
TCA cycle metabolites, aconitic acid and malate, were shared by both conditions. It is known 
that trivalent iAs, at high doses, can inhibit pyruvate dehydrogenase by binding directly [137]. 
This mode of action has also been suggested to decrease ATP production.   
In the context of disease specificity, we identified a set of 59 U-tAs-associated 
metabolites that were unique to the diabetic individuals, specifically 42 U-tAs-associated urinary 
metabolites and 17 U-tAs-associated plasma metabolites. Among these diabetes-specific 
metabolites were those that play a role in two major areas of human metabolism: (1) the TCA 
cycle and energy related pathways (succinate, fumarate, taurine), and (2) amino acid metabolism 
(glycine, serine, methionine, lysine, proline, 5-aminolevulinic acid, glutaric acid, carnitine, 
tyrosine, phenylglyoxylic acid).  Within this group of metabolites are also those associated with 
metabolism of three major B vitamins: biotin, riboflavin and thiamine.  Notably, these vitamins 
are known for their roles in both the energy and amino acid metabolism. Additionally, both 
deficiencies for riboflavin and thiamine have been shown to be associated with increased 
incidence of skin lesions in human populations [138]. Also, methionine and thiamine, in 
conjunction with other antioxidants, have been shown to reverse the oxidative stress burden in 
target organs of mice exposed to arsenic [139].  
While diabetes developed in the presence of chronic exposure to arsenic has been often 
referred to as Type-2 diabetes, an exact disease phenotype is only poorly characterized.  When 
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we compared the 59 U-tAs-associated metabolites unique to diabetic individuals in the 
Chihuahua cohort with the previously published Type 2 diabetes-associated metabolites [115, 
140, 141] or metabolites that predict the risk of Type 2 diabetes  [141] we found only 12 shared 
metabolites: 3-hydroxy-3-methylglutaric acid, carnitine, citrulline, delta-hydroxylysine, glycine, 
lysine, malate, methionine, proline, succinate, tyrosine, and taurine even though all of 
metabolites were represented [115]. Thus, most of the metabolites that shifted in the urine or 
plasma of diabetic individuals in response to arsenic exposure were not among the Type 2 
diabetes-associated metabolites reported in previous studies.  These results point to a unique 
phenotype of arsenic-associated diabetes apparent at the level of the metabolome. It is possible 
that the U-tAs-associated metabolites unique to diabetic individuals represent a metabolomic 
fingerprint of arsenic-associated diabetes.   
While an apparent metabolomics phenotype of arsenic-associated diabetes begins to 
emerge, this study is not without limitations. Most importantly, it was not possible to establish 
whether diabetic individuals’ metabolomics differences were due to diabetes developing as a 
result of arsenic exposure or if diabetic individuals respond differently to arsenic. The response 
of an individual to environmental exposures is multifactorial. For this reason, the analysis 
performed controlled for factors known to influence disease such as age, BMI, and gender. As 
with similar study designs, it is not possible to assess the roles played by genetic susceptibility, 
diet and other lifestyle factors.  Another limitation of this study was U-tAs was not strongly 
correlated to DW-iAs suggesting the potential for additional sources of iAs exposure, such as 
diet and occupational exposures. In addition, it is not possible to directly compare the 
metabolomes between diabetic and non-diabetic individuals as they were matched on levels of 
arsenic exposure. Further investigations, including both population-based and laboratory models, 
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are necessary to determine perturbation of these metabolites is a potential mechanism by which 
arsenic influences diabetes status.  
Taken together there are three major findings from this study: first, we have identified 
more than 100 metabolites that are altered in urine and plasma in response to arsenic exposure. 
Second a set of these metabolites was identified that differentiates diabetic individuals from non-
diabetic individuals. Third, only a minimal overlap was observed between previously identified 
Type 2 diabetes-associated metabolites and the diabetes-specific arsenic exposure-associated 
metabolites, representing a putative fingerprint of arsenic-associated diabetes. These data provide 
insight into the complex mechanism of action of arsenic-associated disease in human populations 
with relevance to millions around the globe. 
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CHAPTER 2: METHYLATED URINARY ARSENICALS TIED TO METABOLOMIC 
PROFILES IN DIABETIC AND NON-DIABETIC INDIVIDUALS EXPOSED TO 
ARSENIC IN MEXICO 
 
2.1 Overview 
Exposure to inorganic arsenic (iAs) is associated with diabetes mellitus (DM), with 
alterations apparent at the level of the metabolome. As demonstrated in the previous chapter, 
arsenic exposure, as measured by total urinary arsenic (U-tAs) is associated with alterations of 
the metabolome in both diabetic and non-diabetic individuals. More recently it has been shown 
that arsenic metabolism is associated with risk of disease development. Inter-individual 
differences in levels and proportions of inorganic arsenic, monomethylated arsenic (MMAs) and 
dimethylated arsenic (DMAs) in urine have all be shown to impact disease susceptibility in 
numerous populations. In the case of DM, increased risk of disease development has been 
associated with increased proportions and levels of DMAs, as measured in urine across multiple 
cohorts. 
The goal of this work was to determine whether metabolomics profiles associated with 
percentages of arsenicals in urine would be similar or different between diabetic and non-
diabetic subjects. The percentages of iAs, MMAs, and DMAs in urine were calculated for 90 
diabetic and 86 non-diabetic individuals. Using multivariable linear regression, we then assessed 
alterations in metabolomics profiles in relationship to each of the arsenical percentages. 
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Additionally, the profiles identified in relation to the arsenical measures were compared to 
those identified in association with U-tAs for similarities and differences. 
Of 426 unique metabolites tested, 89 urinary and 80 plasma metabolites displayed significant 
relationships to at least one of the urinary arsenicals. We found associations with metabolites 
previously associated with diabetes among non-diabetic individuals and unique alterations in 
metabolomics profiles of diabetic individuals. These results highlight there is significant impact 
of iAs metabolism on metabolomic profiles of diabetes and non-diabetes individuals as diabetic 
individuals displayed more shifts in urinary metabolites while non-diabetic individuals displayed 
more alterations in plasma metabolites. Furthermore, these results demonstrate the important role 
of arsenic metabolism in disease development as many of the %DMAs associated metabolites 
have been previously linked to diabetes development.  
2.2 Study Objectives 
In this study, impacts of arsenic metabolism on metabolomic profiles were assessed.  The 
426 unique urine and plasma metabolites identified previously were tested against percentages of 
arsenic metabolites, inorganic arsenic (iAs), monomethylated arsenic (MMAs) and dimethylated 
arsenic (DMAs) in urine using multivariable linear regression. We determined arsenical-
associated metabolomics profiles separately for diabetic and non-diabetic individuals. We then 
used pathway analysis to examine the context related to the changes we observed in metabolite 
alterations. The findings of this research suggest that arsenic metabolism maybe associated with 
diabetes development in the presence of arsenic exposure.  
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2.3 Materials and Methods  
2.3.1 Measurement of Speciated Arsenicals 
The concentrations of inorganic and methylated As species in urine were measured using 
hydride generation-atomic absorption spectrometry coupled with a cryotrap (HG-CT-AAS)[125]. 
As stated previously Arsenic Species in Frozen Human Urine (SRM 2669; National Institute of 
Standards and Technology, Gaithersburg, MD) was used as the certified standard reference 
material. Concentrations of iAs species measured in SRM 2669 by HG-CT-AAS ranged from 
86.7 to 106.4% of the certified values. The limit of detection (LOD) for iAs species in urine was 
0.01 µg As/L. The pattern of iAs metabolism was characterized using the percentage of tAs 
present as DMAs, MMAs, and iAs.  
2.3.2 Statistical Analyses 
For this analysis percentages of each of the arsenicals, %iAs, %MMAs, and %DMAs, were 
assessed for associations with the abundance levels of 221 plasma metabolites and 294 urinary 
metabolites using Partek® Genomics SuiteTM Software (St. Louis, MO) (Table 2). Multivariable 
linear regression analyses were used to assess the relationship between the 426 unique 
metabolites profiled between the urine and plasma matrices and each of the arsenicals. The 
analyses were conducted separately for diabetes and non-diabetes individuals to assess 
differences and similarities between groups. We controlled for covariates with known 
associations with diabetes and arsenic exposure, specifically drinking water iAs, BMI, age and 
sex. Statistical significance was set at p<0.05, q<0.2 to maintain comparability to our previously 
published study.   
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2.3.3 Metabolic pathway analysis 
Canonical metabolic pathway analysis was performed for statistically significantly 
metabolites using the pathway analysis tool within the MetaboAnalyst package.  This tool maps 
metabolites onto KEGG pathways and uses a Fisher’s Exact Test to determine enrichment of 
molecules and a Relative-between Centrality test to determine the impact of the alterations. 
Human Metabolome Database (HMDB) identifiers were used for these analyses as they provided 
greater coverage of metabolites than did the metabolite names. Statistical significance was set at 
p<0.05 for the pathways analysis, as metabolite lists were pre-filtered 
2.4 Results 
2.4.1 Metabolomic profiles associated with arsenic metabolites in urine and plasma  
We assessed the relationships among the indicators of iAs metabolism, namely inorganic 
arsenic (iAs), monomethylated arsenic (MMAs) and dimethylated arsenic (DMAs) in urine and 
metabolomics profiles in urine and plasma. We identified a total of 80 urinary metabolites and 89 
plasma metabolites that were associated with at least one of the urinary arsenicals (e.g. %iAs, 
%MMAs, %DMAs) in either diabetes or non-diabetes individuals (Table 5, Supplemental Table 
3). Of the 80 urinary metabolites, n=38 were identified in non-diabetes individuals and n=56 were 
identified in non-diabetes individuals (Table 5).  Among the urinary metabolites identified in non-
diabetes individuals, n=18 were associated with %iAs, n=16 were associated with %MMAs and 
n=24 were associated with %DMAs (Table 5). In diabetes individuals, n=28 were associated with 
%iAs, n=27 were associated with %MMAs, and n=19 were associated with %DMAs (Table 5). 
Of the 89 plasma metabolites, n=52 were identified in non-diabetes individuals and n=37 were 
identified in diabetes individuals (Table 5). Among the plasma metabolites identified in non-DMs, 
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n=24 were associated with %iAs, n=27 were associated with %MMAs and n=38 were associated 
with %DMAs (Table 5). In diabetes individuals, n=17 plasma metabolites were associated with 
%iAs, n=16 metabolites were associated with %MMAs and n=18 metabolites were associated with 
%DMAs (Table 5).    
   Non-Diabetic Individuals 
(n=86) 
Diabetic Individuals 
(n=90) 
Urine (n=80 metabolites)  38 56 
%iAs  18 28 
%MMAs  16 27 
%DMAs  24 19 
Plasma  (n=89 metabolites)  52 37 
%iAs  24 17 
%MMAs  27 16 
%DMAs  38 18 
Table 5. Number of metabolites identified in association with %iAs, %MMAs, and %DMAs in 
urine and plasma for non-diabetic and diabetic individuals. 
2.4.2 Comparison of metabolomic profiles associated with arsenic metabolites in urine 
  and plasma  
When comparing the altered metabolomics profiles in diabetes and non-diabetes individuals 
we observed little overlap (Figure 3). Among urinary metabolites, two %iAs-associated, two 
%MMAs-associated, and one %DMAs-associated metabolite were shared between diabetes and 
non-diabetes individuals (Figure 4a). Similarly, among plasma metabolites five %iAs-associated, 
one %MMAs associated were shared between diabetic and non-diabetic individuals (Figure 4b). 
No %DMAs-associated metabolites were shared between diabetes and non-diabetes individuals 
(Figure 4b). 
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Figure 4. Comparison of urinary (a) and plasma (b) associated with percentages of arsenic 
metabolites in urine between diabetic and non-diabetic individuals. 
 We also sought to understand the relationship between the arsenical profiles. We found 
substantial overlap between the profiles associated with %iAs and %DMAs and those associated 
with %MMAs and %DMAs in urine and plasma (Figure 5). Interestingly, there were only 4 
overlapping metabolites in both urine and plasma between the profiles predicted by %MMAs 
and %iAs (Figure 4, Supplemental Table 3). Furthermore, there were eight metabolites shared 
between all three metabolomic profiles in both urine and plasma. In non-diabetic individuals, 
there were a total 7 urinary and 8 plasma metabolites uniquely associated with %iAs, 7 urinary 
and 6 plasma metabolites associated with %MMAs and 5 urinary and 6 plasma metabolites 
associated with %DMAs (Figure 5). Interestingly among the plasma metabolites which 
overlapped between %MMAs and %DMAs in diabetic individuals, there were a total 17 urinary 
and 9 plasma metabolites uniquely associated with %iAs, 19 urinary and 9 plasma metabolites 
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associated with %MMAs and 4 urinary and 3 plasma metabolites associated with %DMAs 
(Figure 5). Among the profiles, %MMAs has the most uniquely associated metabolites, with a 
total of 13 %MMAs unique metabolites in non-diabetic and 28 metabolites in diabetic 
individuals (Figure 5). Conversely, %DMAs has the least uniquely associated metabolites with 
11 %DMAs-unique metabolites in non-diabetic individuals and 7 metabolites in diabetic 
individuals (Figure 5).  
 
Figure 5. Comparison of urinary (a) and plasma (b) metabolites between arsenical associated 
percentages in diabetic and non-diabetic individuals. 
2.4.3 Pathway analysis of %iAs associated metabolites.  
We identified a set of pathways in association with arsenic exposed non-diabetic and 
diabetic individuals in association with each arsenical for the urine and plasma matrices 
separately. In the case of %iAs, we identified no pathways enriched by the 18 urinary 
metabolites and two pathways enriched by the 24 plasma metabolites in non-diabetic individuals 
(Table 6). In contrast to this, we identified a total of five pathways enriched by the 28 urinary 
metabolites and one pathway enriched by the 17 plasma metabolites in diabetic individuals. We 
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saw no overlap of pathways between diabetic and non-diabetic individuals exposed (Table 6). 
The majority of pathways we identified were either associated with carbohydrate metabolism 
(Fructose and mannose metabolism, TCA Cycle) and amino acid metabolism (Cyano-amino acid 
metabolism, alanine, aspartate and glutamate metabolism, and aminoacyl-tRNA biosynthesis).  
Pathway Name # Molecules p-value Impact 
Non-Diabetic Individuals 
Urinary Metabolites       
-    
Plasma Metabolites     
Pantothenate and CoA biosynthesis 2 0.0074642 0.02002 
Fructose and mannose metabolism 2 0.022631 0.0545 
Diabetic Individuals  
Urinary metabolites        
Cyanoamino acid metabolism 2 0.006634 0 
Citrate cycle (TCA cycle) 2 0.010308 0.06957 
Alanine, aspartate and glutamate metabolism 2 0.014695 0.02279 
Aminoacyl-tRNA biosynthesis 3 0.019664 0.05634 
Methane metabolism 2 0.028502 0.01751 
Plasma Metabolites    
Pyrimidine metabolism 3 0.00048 0.07207 
Table 6. Pathways enriched for by %iAs associated metabolites in urine and plasma in diabetic 
and non-diabetic individuals 
2.4.4 Pathway analysis of %MMAs associated metabolites 
Enrichment of %MMAs associated metabolomic profiles revealed one pathway enriched 
by the 16 urinary metabolites and three pathways enriched by the 27 plasma metabolites in non-
diabetic individuals (Table 7). In diabetic individuals, we identified a total of seven pathways 
enriched by the 27 urinary metabolites and five pathway enriched by the 16 plasma metabolites 
(Table 7). We saw overlap of pathways between diabetic and non-diabetic individuals exposed: 
Phenylalanine, tyrosine and tryptophan biosynthesis and Phenylalanine metabolism were 
enriched in both groups (Table 7). The majority of pathways we identified were either associated 
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with amino acid metabolism (Phenylalanine metabolism, phenylalanine, tyrosine and tryptophan 
metabolism, valine, leucine and isoleucine metabolism, alanine, aspartate and glutamate 
metabolism, D-glutamine and D-glutamate metabolism and aminoacyl-tRNA biosynthesis).  
Pathway Name # Molecules p-value Impact 
Non-Diabetic Individuals  
Urinary Metabolites    
Phenylalanine metabolism 2 0.020028 0 
Plasma Metabolites    
Phenylalanine, tyrosine and tryptophan biosynthesis 3 0.0012644 0.008 
Valine, leucine and isoleucine biosynthesis 3 0.0012644 0.05194 
Propanoate metabolism 3 0.0027115 0.00134 
Aminoacyl-tRNA biosynthesis 4 0.0028846 0 
Nitrogen metabolism 3 0.0037066 0 
Valine, leucine and isoleucine degradation 3 0.0039859 0.06442 
Phenylalanine metabolism 3 0.0055747 0.11906 
Citrate cycle (TCA cycle) 2 0.011396 0.01446 
Diabetic Individuals 
Urinary Metabolites       
Phenylalanine metabolism 3 0.004096 0.02373 
Phenylalanine, tyrosine and tryptophan biosynthesis 2 0.016601 0.00738 
Ubiquinone and other terpenoid-quinone biosynthesis 2 0.028637 0.04886 
Plasma Metabolites        
Alanine, aspartate and glutamate metabolism 2 0.004085 0.02279 
Butanoate metabolism 2 0.011141 0.0048 
Glyoxylate and dicarboxylate metabolism 2 0.017112 0.00686 
Synthesis and degradation of ketone bodies 1 0.024695 0 
D-Glutamine and D-glutamate metabolism 1 0.044854 0 
Table 7. Pathways enriched for by %MMAs associated metabolites in urine and plasma in 
diabetic and non-diabetic individuals 
 
2.4.5 Pathway analysis of %DMAs associated metabolites 
Lastly, we performed pathway enrichment on metabolomic profiles associated with 
%DMAs in urine and plasma for diabetic and non-diabetic individuals. We found that there was 
one pathway enriched by the 24 urinary metabolites and three pathways enriched by the 38 
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plasma metabolites in non-diabetic individuals (Table 8). In contrast to this, we identified a total 
of seven pathways enriched by the 19 urinary metabolites and two pathway enriched by the 18 
plasma metabolites in diabetic individuals (Table 8). We saw no overlap of pathways between 
diabetic and non-diabetic individuals exposed (Table 8). The majority of pathways we identified 
were either associated with amino acid metabolism (Alanine, aspartate and glutamate 
metabolism, valine, leucine and isoleucine biosynthesis, and Phenylalanine, tyrosine and 
tryptophan biosynthesis).  
Pathway Name # Molecules p-value Impact 
Non-diabetic Individuals 
Urinary Metabolites       
Alanine, aspartate and glutamate metabolism 2 0.0092452 0.06837 
Plasma Metabolites       
Citrate cycle (TCA cycle) 3 0.000169 0.13021 
Nicotinate and nicotinamide metabolism 2 0.025856 0.02448 
Glyoxylate and dicarboxylate metabolism 2 0.032822 0.02811 
Diabetic Individuals 
Urinary Metabolites    
Valine, leucine and isoleucine biosynthesis 3 0.0014641 0.05194 
Aminoacyl-tRNA biosynthesis 4 0.00348 0 
Valine, leucine and isoleucine degradation 3 0.004597 0.06442 
Phenylalanine, tyrosine and tryptophan biosynthesis 2 0.02232 0.008 
Tryptophan metabolism 3 0.029564 0.06049 
Propanoate metabolism 2 0.036288 0 
Nitrogen metabolism 2 0.044259 0 
Plasma Metabolites    
Synthesis and degradation of ketone bodies 1 0.027137 0 
Pyrimidine metabolism 2 0.029086 0.05715 
Table 8. Pathways enriched for by %DMAs associated metabolites in urine and plasma in 
diabetic and non-diabetic individuals 
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2.4.6 Comparison of pathways enriched for by arsenical-associated metabolomics profiles 
When comparing enriched pathways for %iAs, %MMAs, and %DMAs, we find that there are 
overlaps as well as uniquely associated profiles. Interestingly, the Citric acid cycle, Aminoacyl-
tRNA biosynthesis, Phenylalanine, tyrosine and tryptophan biosynthesis, and Alanine, aspartate 
and glutamate metabolism were shared among all arsenical-associated metabolomics profiles in 
both diabetic and non-diabetic individuals.  Pyrimidine metabolism was enriched for by both 
%iAs and %DMAs associated metabolomic profiles in Diabetic individuals only. Additionally, 
there were many commonalities shared between %MMAs and %DMAs in non-diabetic 
individuals including Valine, leucine and isoleucine synthesis, Nitrogen metabolism and 
Propanoate metabolism. Among diabetic individuals, Glycoxylate/dicarboxylate metabolism, and 
Synthesis of ketone bodies were shared between %MMAs and %DMAs. There were no unique 
pathways among non-diabetic individuals. However, among diabetic individuals, plasma 
metabolites associated with %MMAs uniquely enriched for D-glutamine and D-glutamate 
metabolism and Butanoate Metabolism. Additionally, urinary metabolites associated with 
%MMAs enriched for Nicotinate and nicotinamide metabolism, and urinary metabolites 
associated with %iAs enriched for Ubiquinone and terpenoid-Quinone biosynthesis.  
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2.5 Discussion 
Given that arsenic-associated diabetes has been previously associated with arsenic 
metabolism, specifically increased proportions of %DMAs [37, 50], we set out to determine 
whether arsenic metabolism impacts metabolomic profiles in diabetic and non-diabetic 
individuals exposed to arsenic. We identified a total of 80 urinary metabolites and 89 plasma 
metabolites associated with at least one arsenical in either diabetic or non-diabetic subjects. 
Additionally, there was little overlap between metabolomic profiles associated with arsenicals 
for diabetic and non-diabetic individuals exposed to arsenic. Additionally, we found that profiles 
associated with %iAs, %MMAs and %DMAs shared moderate overlap. Lastly we found that the 
majority of these metabolites enriched for amino acid metabolism and carbohydrate metabolism. 
However, a distinct group of pathways was uniquely associated with arsenicals in diabetic 
individuals. Taken together these data suggest that arsenic-metabolism contributes to 
development of arsenic associated diabetes.  
We found there was minimal overlap between diabetic and non-diabetic individuals exposed 
to arsenic. There were a total of 9 overlapping probes between the metabolites identified in 
diabetic and non-diabetic subjects. This represents a total of 8% of probes that were shared 
between diabetic and non-diabetic individuals.  This contrasts our previously published profile of 
U-tAs associated profiles where we saw a 30% of metabolites common to diabetes and non-
diabetes individuals [69]. Furthermore, when comparing the arsenical associated metabolomic 
profiles to each other there was substantial overlap between %MMAs associated metabolomic 
profiles and %DMAs associated metabolic profiles as well as between %iAs associated 
metabolomic profiles and %DMAs associated metabolomic profiles. The differences between 
profiles associated is interesting as this suggests that there may be effects of arsenic metabolism 
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on other metabolic processes. These results suggest that arsenic metabolism may play a role in 
disease development as diabetic and non-diabetic individuals separate out more readily when 
assessing arsenic metabolite associated metabolomic profiles as compared to total urinary 
arsenic-associated metabolomic profiles.  
Pathway analysis revealed that there were substantial alterations associated with amino acid 
metabolism. This finding mirrors our previous find where amino acid metabolism was a key 
category altered in association with total urinary arsenic [69]. Additionally, it is interesting as it 
has been previously shown that arsenic exposure is associated with alterations in amino acid 
metabolism and similar associations are also associated with development of diabetes. 
Furthermore, only a few unique pathways were identified. Interestingly these pathways were all 
found in diabetic individuals.  Specifically, among diabetic individuals, plasma metabolites 
associated with %MMAs uniquely enriched for D-glutamine and D-glutamate metabolism and 
butanoate Metabolism. Interestingly glutamine/glutamate ratios and butanoate have been 
associated with traditional type 2 diabetes [142-144]. It has also been shown that enzyme 
involved in glutamate metabolism are altered by exposure to arsenic [88, 145]. We also observed 
that urinary metabolites associated with %MMAs enriched for Nicotinate and nicotinamide 
metabolism, which has been implicated in glucose control and is of interest in the treatment of 
diabetes [146-148].  Interestingly, it has also been shown that arsenic perturbs enzymes involved 
nicotinamide and nicotinate metabolism [121, 149] and supplementation of nicotinamide reduces 
arsenic-induced skin cancer [150]. Interestingly these pathways are linked to arsenic as well as 
development of diabetes. This suggests that arsenic metabolism may have effects of processes 
related to arsenic-associated metabolism.    
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As %DMAs have been associated with diabetes [37, 50], we were particularly interested in 
examining the associated metabolites associated with these pathways. Pathway analysis of the 37 
%DMAs-associated metabolites revealed an enrichment for the citric acid (TCA) cycle. In prior 
work, we previously observed disruption of metabolites within the TCA cycle in association with 
total urinary arsenic (U-tAs) in diabetes individuals [69].  In the present study, decreases in the 
levels of TCA intermediates fumarate, isocitrate, and cis-Aconitic acid were observed in relation 
to %DMAs. In our previous work, U-tAs was associated with increases of fumarate and 
succinate in diabetes individuals [69]. These results suggest a general dysregulation of the TCA 
cycle in relation to iAs exposure, supported by prior studies as well [151]. Our results are further 
supported by research that demonstrates diabetes subjects have decreased muscular TCA cycle 
flux, which have been attributed to mitochondrial dysfunction, and enzymatic disruptions of key 
TCA cycle enzymes [142, 152]. Taken together, these data suggest that differences in iAs-
metabolism may be related to dysregulation of the TCA cycle in exposed diabetes individuals.  
In addition to the examination of iAs-associated metabolomic profiles in diabetes subjects we 
also examined profiles in non-diabetes individuals. Interestingly, increases in %DMAs were 
associated with increases in levels of the following five amino acids: valine, leucine, isoleucine, 
phenylalanine, and tyrosine. These metabolites are of special interest as their increased serum 
levels have been associated with increased odds of diabetes development prior to diagnosis [153, 
154]. Interestingly, diabetes individuals did not display differences in these amino acids levels in 
relation to iAs metabolism indicators. As mechanistic studies have linked amino acid metabolism 
to insulin resistance and subsequent development of DM, these data could provide insight into 
which mechanisms are relevant to iAs-induced diabetes [122]. Future research could focus on 
whether these amino acids serve as biomarkers for diabetes in iAs-exposed individuals.  
51 
 
Our results demonstrate that when analyzed in the context of methylated urinary arsenicals 
proportions, there are substantial differences between metabolomics profiles of diabetes and non-
diabetes individuals. These result further substantiate that inter-individual differences in iAs 
metabolism is important to understand iAs-associated disease.  Furthermore, we demonstrate that 
metabolomic changes observed in association with %DMAs reflect critical biochemical 
pathways. These pathways provide novel information on the mechanisms by which %DMAs 
may be tied to DM. Metabolomics is a powerful tool for identifying mechanisms underlying iAs-
associated disease, and identifying potential disease biomarkers.   
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CHAPTER 3: ARSENIC-3-METHYLTRANSFERASE (AS3MT) GENOTYPE IS 
ASSOCIATED WITH UNIQUE METABOLOMIC PROFILES IN DIABETIC AND 
NON-DIABETIC INDIVIDUALS EXPOSED TO ARSENIC IN MEXICO 
 
3.1 Overview 
The enzyme Arsenic-3-Methyltransferase (AS3MT) is primarily responsible for metabolism 
of inorganic arsenic. Arsenic metabolism is an important indicator of disease susceptibility with 
%DMAs being associated with diabetes susceptibility.  Interestingly genotype of AS3MT has 
been associated with alterations in percentages of arsenic metabolites. Furthermore, a subset of 
these are associated with increased risk for numerous iAs-associated diseases including Diabetes 
Mellitus (DM). Taken together these data support the hypothesis that the metabolism of iAs into 
its methylated metabolites influences diabetes risk.  
Given that iAs-associated diabetes is also associated with differences at the level of the 
metabolome, as well as observed differences between metabolomics profiles associated with 
arsenic metabolism, we set out to understand the relationship between genotype of AS3MT and 
the metabolome. To elucidate potential pathways that AS3MT might influence resulting in inter-
individual differences in diabetes risk, metabolomic profiles from diabetes and non-diabetes 
individuals were analyzed in both a stratified and non-stratified manner, for associations with six 
single nucleotide polymorphisms (SNPs) of AS3MT were analyzed in association with the 426 
urinary and plasma metabolites assessed during untargeted metabolomic assessment.  
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A total of four SNPs, rs17881215, rs3740393, rs3740390 and rs10748835 were associated 
with 36 urinary and plasma metabolites in stratified and non-stratified modeling. Many of these 
metabolites have been previously associated with type 2 DM. Additionally, these metabolites 
were associated with diabetes associated processes such as glucose metabolism, amino acid 
metabolism and riboflavin metabolism. Given the relationship of these metabolites and AS3MT, 
it is possible that arsenic metabolism impacts metabolic processes related to diabetes thus 
influencing inter-individual susceptibility to arsenic-induced DM. These metabolites could help 
inform a mechanistic understanding by which arsenic is able to induce diabetes in humans, as 
well as serve as potential pathways for targeting of intervention strategies.  
3.2 Study Objectives 
In the present study, metabolic impacts of AS3MT not related directly to arsenic metabolism 
were assessed. This was done by integrate metabolomic profiles and genotype data sets. There 
were a total of 123 individuals, 67 non-diabetic and 56 diabetic individuals, for analysis. 
Individuals were coded has having zero, one or two copies of the variant allele for each SNP. 
Their SNP profile was then compared individually to each of the 426 urinary and plasma 
metabolites. This was done in both a non-stratified and stratified models. Taken together the 
results of this analysis suggest that arsenic metabolism may impact metabolic processes related 
to diabetes development and thus provide a mechanistic link between arsenic-metabolism and 
disease susceptibility.  
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3.3 Materials and Methods 
3.3.1 Cohort Selection 
A total of 1,165 adults (≥18 years old) with a minimum of 5-year uninterrupted residency in the 
study area were recruited between 2008 and 2012 [123, 124].  Individuals were excluded if 
pregnant, occupational exposed to arsenic, or reported kidney or urinary tract infection as these 
conditions may affect profiles of arsenic metabolites in urine. Drinking water samples were 
obtained from each subjects’ households, and an interviewer-administered study questionnaire 
was used to record data on residency, occupation, drinking water sources and use, smoking, 
alcohol consumption, and medical history.  During medical exams, spot urine and fasting venous 
blood were collected and an oral glucose tolerance test with blood drawn 2 hours after a 75 g 
glucose dose.  Plasma from both fasting and two-hour blood samples and urines were 
immediately frozen and stored at -80oC.  Measures of body weight and height were obtained 
during the exams and used to calculate body mass index (BMI). All procedures involving human 
subjects were approved by the IRBs of UNC Chapel Hill and Cinvestav-IPN, and all participants 
signed a written consent to participate in the study.   
As described previously, 176 individuals, comprising 90 diabetic and 86 non-diabetic 
individuals, had been selected and profiled by metabolomics assessment [69]. A separate subset 
of individuals (n=543 individuals) had been previously assessed for AS3MT genotypes [155]. 
Between the two groups, 123 individuals, 67 non-diabetic and 56 diabetic individuals, had both 
genotyping and metabolomics profiles available for assessment.   
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3.3.2 Genotyping assessment 
DNA was isolated from venous blood collected during the oral glucose tolerance test 
using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer’s protocol. A 
total of eight AS3MT single nucleotide polymorphisms (SNPs) were selected for analysis given 
their relationships to arsenic metabolism and or susceptibility to toxicity. The SNPs selected for 
analysis were:  rs35232887, rs34556438, rs11191439, rs17881215, rs3740393, rs3740390, 
rs11191453, and rs10748835. Predesigned TaqMan (Applied Biosystems, Carlsbad, CA, USA) 
assays were used to assess alleles of the SNPs at either the Mammalian Genotyping Core (UNC, 
Chapel Hill, North Carolina, USA) or in the Mendez laboratory (rs17181215). The ABI 
Dual384-Well GeneAmp PCR System 9700 and ABI PRISM 7900 HT-Sequence Detection 
System from Applied Biosystems was used for genotyping and the ABI SDS software for data 
analysis. VNTR variants and rs17881215 were identified by sequencing a PCR-amplified 
promoter region. Due to genotyping failure and lack of variability, rs35232887 and rs34556438 
were not considered for further analysis.   
3.3.3 Statistical Analysis 
All statistical analyses were carried out using Partek Genomic Suite (St. Louis, MO). SNP 
genotypes were numerically coded as zero (wild type homozygote, zero copies of the minor/less 
common allele), one (heterozygote, one copy of the minor allele) or two (variant homozygote, 
two copies of the minor allele).  
Multivariable linear regression was performed to examine the relationships between each of 
the six AS3MT SNPs, to each of the 294 urinary and 221 plasma metabolites. This allowed for 
comparisons to the primary predictor of AS3MT genotype, while controlling for the effects of 
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several important cofounders known to affect arsenic metabolism: age, sex, BMI, and drinking 
water iAs levels.  The data were analyzed for outliers and determined not to be influenced by 
outliers. Five models were constructed and tested. The primary model (Model I) included all 
individuals testing AS3MT genotype as a predictor. Additionally, given that we observed 
different metabolomics profiles for diabetic and non-diabetic subjects in association with arsenic 
exposure, subjects were stratified as non-diabetic individuals (Model II) and diabetic individuals 
(Model III). Beta (β) coefficients were calculated representing the estimated change in 
metabolite levels given the addition of one copy of the minor allele. To determine these, the 
referent group was the wild type homozygous group carrying zero copies of the minor allele, was 
compared to the heterozygote group carrying one copy of the minor allele. Statistical 
significance was set at p ≤ 0.05, q<0.1. 
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3.4 Results 
3.4.1 Demographic Assessment 
 There were 123 individuals (67 non-diabetic and 56 diabetic individuals) profiled for this 
analyses. These individuals were similar in terms of age (non-diabetic individuals mean=50.0, 
diabetic individuals mean=51.5) sex (female non-diabetic individuals-71.6%, female diabetic 
individuals-76.8%), and BMI (non-diabetic individuals mean=29.2, diabetic individuals 
mean=29.8) (Table 9). The individuals did differ substantially in their fasting plasma glucose 
(FPG) (non-diabetic individuals mean= 88.7, diabetic individual mean=167.1) and 2-hour blood 
glucose level (2HPG) (non-diabetic individuals mean=110.7, diabetic individuals mean=213.7). 
Their levels of arsenic exposure were similar with non-diabetics exposed to 67.3 µg/L iAs in 
drinking water and diabetic individuals exposed to 78.2 µg/L drinking water on average (Table 
9).  
 All Individuals 
(n=123) 
Non-Diabetic 
Individuals 
(n=67) 
Diabetic 
Individuals  
(n= 56) 
p-value 
     
Sex     
Male 32 (26.0%) 19 (28.4%) 13 (23.2%)  
Female 91 (74.0%) 48 (71.6%) 43 (76.8%)  
Age 50.7 (18-79) 50.0 (18-78) 51.5 (23-79) 0.555 
BMI 29.5 (18.3-43.6) 29.2 (19.2-43.6) 29.8 (18.3-43.1) 0.557 
FPG (mg/dL) 124.4 (49.5-279) 88.7(49.5-121) 167.1 (69-397) <0.001 
2HPG (mg/dL) 157.2 (50-437) 110.7 (50-176.5) 213.7 (50.5-437) <0.001 
DW-iAs (µg/L) 72.3 (<LOD-292.9) 67.3 (<LOD-284.7) 78.2 (<LOD-292.9) 0.396 
Table 9. Demographics for individuals with both in the AS3MT genotyping and metabolomic 
analysis. 
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3.4.2 General Polymorphic Characteristics  
 The individuals analyzed were categorized into one of three categories depending upon 
their genotypes: wild-type homozygotes (i.e., carriers of two copies of the major allele), variant 
homozygotes (carriers of two copies of the minor allele) or heterozygotes (carriers of one copy 
of the major allele and one copy of the minor allele). Five of the tested SNPs are located within 
intronic regions (rs17881215, 3740393, rs3740390, rs11191453, rs10748835) of AS3MT (Figure 
6). One non-synonymous SNP present in exon nine alters the amino acid sequence (Met287Thr) 
of the AS3MT protein (rs1191439). All tested SNPs have been previously associated with 
increased proportion of DMAs in urine (Figure 6), a risk factor for DM.  
 
Figure 6. Location of SNP Positions within the AS3MT gene. Adapted from Drobna 2016 
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Allelic frequencies were generally consistent with those found in the larger group of individuals 
analyzed (Xu 2016) (Table 10).  All examined SNPs passed the Hardy-Weinberg equilibrium test 
at p < 0.05 (Table 10).  
 All Individuals Non-Diabetic 
Individuals 
Diabetic 
Individuals 
Xu 2016 
rs11191439 T: 0.93 (229) 
C: (0.07) 17  
T: 0.95 (127)  
C: 0.05 (7) 
T: 0.91(102) 
C: 0.09 (10) 
T: 0.91 
C: 0.09 
rs11191453 T: 0.78 (192)  
C: 0.22 (54) 
T: 0.78(104) 
C: 0.22 (30) 
T: 0.79 (88) 
C: 0.21 (24) 
T: 0.79 
C: 0.21 
rs3740393 G: 0.72(178) 
C: 0.28 (68) 
G: 0.73 (98) 
C: 0.27 (36) 
G: 0.71 (80) 
C: 0.29 (32) 
G: 0.75 
C: 0.25 
rs3740390 C: 0.74 (183) 
T: 0.26 (63) 
C: 0.75 (101) 
T: 0.25 (33) 
C: 0.73 (82) 
T: 0.27 (30) 
C: 0.77 
T: 0.23 
rs10748835 A: 0.57(139) 
G: 0.43 (107) 
A: 0.57 (77) 
G: 0.43 (57) 
A: 0.55 (62) 
G: 0.45 (50) 
A: 0.55 
G: 0.45 
rs17881215 G: 0.92 (226) 
C: 0.08 (20) 
G: 0.93 (125) 
C: 0.07 (9) 
G: 0.90 (101) 
C: 0.10 (11) 
G: 0.90 
C: 0.10 
Table 10. Allelic Frequency Table and comparison to frequencies found within the larger cohort 
published in Xu et al 2016 [155] 
3.4.3 Model 1: Non-stratified modeling reveals associations between four SNPs and 
altered metabolism 
 
 For each of the six SNPs analyzed, multiple variable linear regression was used to 
identify associations between AS3MT alleles and urine and plasma metabolite levels in both 
diabetic and non-diabetic subjects. Of the 294 urinary metabolites analyzed and 221 plasma 
metabolites analyzed, 12 urinary metabolites and one plasma metabolite displayed associations 
with at least one SNP (Table 11). These 12 metabolites were associated with at least one of the 
following four SNPs: rs17881215, rs3740393, rs3740390 and rs10748835 (Table 11). Of the 
urinary metabolites, rs3740390 displayed associations with ten metabolites, including the amino 
acids arginine and phenylalanine, and the glycolysis intermediate glyceraldehyde-3-phosphate 
(Table 11). The majority (n=9, 75%) of the metabolites displayed increased levels in carriers of 
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the variant allele, while only three displayed decreased levels in association with the variant 
allele. The plasma metabolite identified was dodecanoic acid, and it displayed a positive 
association with the presence of the variant allele rs10748835 (Table 11).  
 Urine Metabolites (β-value) Plasma Metabolites (β-value) 
rs17881215  7-Methyl-indole (0.17)** 
5-Hydroxydopamine (0.18)** 
- 
 
rs11191439 - - 
rs11191453 - - 
rs3740393 Glyceraldehyde 3-phosphate (0.17)** - 
rs3740390 Myo-Inositol (0.20)** 
Guanidineacetic acid (0.13)** 
2-Hydroxy-3-methylpentanoic acid 
(0.18)** 
3-Methylindole (0.17)** 
Homovanillic acid (-0.08)** 
N-methyl-L-histidine (-0.25)** 
Phenylalanine (0.22)** 
5-Aminolevulinic acid (-0.31)** 
Arginine (-0.31)** 
- 
rs10748835 - Dodecanoic acid (0.34)** 
Table 11. Statistically significantly associated metabolite-SNP associations in all individuals 
(n=123). Displayed are β coefficients of the linear regression model indicating the direction and 
magnitude of the alteration. * p<0.05, ** p<0.05, q<0.1 
3.4.4 Model 2: Non-diabetic individuals display unique metabolic alterations associated 
  with the four SNPs previously identified in Model 1 
 
 Given that different metabolite profiles have been previously observed for diabetic and 
non-diabetic individuals, we performed stratified analyses for non-diabetic individuals alone 
(Table 12). We found two urinary and four plasma metabolites associated with at least one SNP 
in non-diabetic individuals alone (Table 12). Again the same four SNPs, as detailed above, 
namely rs17881215, rs11191439, rs370393 and rs3740390 showed association with the 
metabolites. As observed among the metabolites identified in Model I, glyceraldehyde 3-
phospate showed a positive association with rs3740393 and, guanidineacetic acid showed a 
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positive association with rs374390 (Table 12). In contrast to Model I, among the plasma 
metabolites, dodecanoic acid showed an association with rs17881215, rather than rs10748835 
(Table 11, Table 12). Additionally, three new metabolites were identified as displaying positive 
associations: tetradecanoic acid was associated with rs17881215, 11-eicosenoic acid was 
associated with rs17881215 and rs11191439, and rs3740390 was associated with 2,5-
dihydroxybenzoic acid (Table 12).  
 Urine Metabolites (β-value) Plasma Metabolites (β-value) 
rs17881215 - Tetradecanoic acid (0.29)** 
11-Eicosenoic acid (0.45)** 
Dodecanoic acid (0.50)** 
rs11191439 - 11-Eicosenoic acid (0.44)** 
rs11191453 - - 
rs3740393 Glyceraldehyde 3-phosphate (0.21)** - 
rs3740390 Guanidineacetic acid (0.22)** 2,5-dihydroxybenzoic acid 
(0.36)** 
rs10748835 - - 
Table 12. Statistically significantly associated metabolite-SNP associations in non-diabetic 
individuals (n=67). Displayed are β coefficients of the linear regression model indicating the 
direction and magnitude of the alteration. * p<0.05, ** p<0.05, q<0.1 
 
3.4.5 Model 3: Diabetic individuals display unique alterations associated with the four 
SNPs previously identified in Model 1 and Model 2 
 
During stratified analyses, diabetic individuals, in addition to non-diabetic individuals, 
were tested alone for associations between genotype and metabolomic profiles. Among diabetic 
individuals we found alterations of 13 urinary metabolites and one plasma metabolite, in 
associations with two SNPs (Table 13). All 13 urinary metabolites were positively associated 
with rs17881215, including 7-methyl-indole and 5-hydroxydopamine, which were found in 
Model 1 (Table 11, 13). Additional metabolites included, oxalic acid, quiolinic acid, ribitol and 
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riboflavin (Table 13). The plasma metabolite identified, Palmitin, was negatively associated with 
the presence of the variant allele for rs1078835 (Table 13).   
 Urine Metabolites (β-value) Plasma Metabolites (β-value) 
rs17881215 Quinolinic acid (0.46)** 
7-Methyl-indole (0.28)** 
3-Desoxypentitol (0.27)** 
Ribitol (0.33)** 
3-Methoxytyrosine (0.33)** 
4-Hydroxy-proline (0.33)** 
Phenylacetylglycine (0.46)** 
Oxalic acid (0.28)** 
2,3-Diaminopropionic acid (0.33)** 
Choline (0.33)** 
5-Hydroxydopamine (0.28)** 
3-Methylglutaric acid (0.29)** 
Riboflavin (0.37)** 
 
rs11191439 - - 
rs11191453 - - 
rs3740393 - - 
rs3740390 - - 
rs10748835 - Palmitin (-0.08)** 
Table 13. Statistically significantly associated metabolite-SNP associations in diabetic 
individuals (n=56). Displayed are β coefficients of the linear regression model indicating the 
direction and magnitude of the alteration. * p<0.05, ** p<0.05, q<0.1 
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3.5 Discussion 
It has been previously demonstrated that arsenic-associated diabetes is likely tied to the 
metabolism of arsenic [37, 50]. The enzyme AS3MT is required for, and has been previously 
associated with alterations in  arsenic metabolism and with increased odds of diabetes 
development [111].  We integrated untargeted metabolomics data and genotypic profiles of 
diabetic and non-diabetic subjects to understand alterations in arsenic metabolism associated 
with other metabolic alterations. Specifically, we profiled six AS3MT SNPs that had been 
previously associated with diabetes and increased proportions of DMAs.  A total of four SNPs 
(rs17881215, rs3740390, rs3740393 and rs10748835) were identified to be associated with 
alterations in 36 urinary and plasma metabolites. Of the SNPs associated with metabolites, 
presence of the variant allele of rs17881215 has been previously associated with diabetes in 
arsenic exposed individuals [111]. These metabolites are linked to processes we identified as 
different between diabetic and non-diabetic individuals exposed to arsenic.  
 Of the metabolites identified several were related to glucose metabolism. Interestingly, SNP 
rs17881215, were associated with differences in levels of oxalic acid, a component of the citric 
acid (TCA) cycle that has been previously associated with diabetes. We also identified oxalic 
acid as altered in relationship to arsenic exposure in diabetic individuals [69].  Additionally, SNP 
rs3740393 was associated with levels of glyceraldehyde-3-posphate in the non-stratified model 
and in non-diabetic individuals. This metabolite is an intermediate metabolite of glycolysis, and 
increased levels are associated with diabetic complications [156]. We had previously identified 
the TCA cycle as a target of potential interest as it was associated with arsenic exposure in both 
diabetic and non-diabetic subjects [69].   
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Several of the identified metabolites identified here in relation to AS3MT genotype were 
related to amino acid metabolites. This is supported by our prior work that showed alterations of 
amino acids, specifically arginine and proline metabolism, previously identified as arsenic-
associated in diabetic and non-diabetic individuals. In the non-stratified model and in non-
diabetic individuals alone, we identified levels of the metabolite guanidineacetic acid, a 
precursor of several amino acids, were associated with SNP rs3740390. Interestingly, we found 
that presence of the variant allele was associated with increased guanidineacetic acid, and a 
decrease of its downstream metabolite, Arginine. In support of this finding, high levels of urinary 
excretion of guanidinoacetic acid have been observed in diabetic rats [157], while decreased 
arginine has been associated with insulin resistance [158]. Additionally, increased levels of the 
amino acid phenylalanine were associated with the variant allele for rs3740390. Increased levels 
of this amino acid have been linked to future development of diabetes [153, 154]. 
We also identified alterations in vitamin metabolism associated with AS3MT genotype.  
Riboflavin, which we identified as altered in diabetic individuals in relation to arsenic exposure, 
was associated with rs17881215 [69]. Interestingly, it has been shown that individuals with 
diabetes have abnormal riboflavin metabolism [159, 160], and we previously showed it to be 
associated with arsenic exposure in diabetic individuals [69]. Furthermore, it is thought that 
riboflavin can help improve glucose control [161, 162].  
The last group of metabolites are associated with metabolic alterations observed in diabetes. 
Of interest was, 5-hydroxydopamine, associated with rs17881215, which was associated in the 
non-stratified model and in diabetic individuals. Treatment of diabetic mice with other 
hydroxydopamine compounds has been shown to result in decreased food intake, weight loss, 
decreased glucose levels and improved pancreatic islet granulation [163, 164]. In contrast to this, 
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rs10748835 was associated with palmitin which has been shown to induce apoptosis in 
pancreatic beta cells [165], one of the mechanisms associated with arsenic-associate diabetes. A 
slight decreased was observed in association in carriers of the variant allele, in contrast to our a 
priori hypothesis that these individuals would have higher levels of palmitin. This could be an 
issue of power, as we had a relatively small sample size.  Additionally, increased levels of the 
plasma metabolites were associated with 11-eicosenoate and tetradecanoic acid were associated 
with the variant alleles of rs17881215. Both rs17881215 and rs10748835 were associated with 
dodecanoic acid.  Interestingly, increases in all three  metabolites have all been previously 
associated with diabetes [166, 167]. Taken together the various metabolites associated with 
rs17881215 are associated with various processes known to be altered in diabetes processes, 
suggesting that there is an association between rs17881215 and alteration of other metabolic 
processes. Finally, the plasma metabolite associated with rs3740390 variant allele, 2,5-
dihydroxybenzoic acid, has been found to be increased in tissues of diabetic rats [168]. The 
metabolites associated with the presence of the variant alleles of rs3740390 were also associated 
with increased risk of diabetes development.  
In conclusion, the variant allele for all SNPs was associated with differences in the levels of 
metabolites and metabolic pathways related to diabetes development. These data suggest that 
arsenic metabolism may impact other metabolic pathways that play a role in diabetes 
development. These findings can inform mechanistic understandings about arsenic-associated 
diabetes and the underlying differences that result in inter-individual differences. This study 
represents a unique integration of genotype and metabolomic profiles to provide insight into 
potential pathways that are related to arsenic metabolism, and inter-individual susceptibility to 
diabetes development in the presence of arsenic exposure.  
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CHAPTER 4: DISSERTATION DISCUSSION, CONCLUSIONS, AND FUTURE 
DIRECTIONS 
 
Metabolomics profiles may provide mechanistic insight into arsenic-associated diabetes 
 Collectively, the studies presented here are part of my dissertation demonstrate that there 
is a relationship between arsenic exposure, arsenic metabolism and inter-individual variability 
that are associated with risk of diabetes development. Specifically, in Chapter 1 we show that 
arsenic exposure, as assessed by U-tAs, is associated with a unique fingerprint of metabolites 
among diabetic individuals that are not mirrored by traditional type 2 DM. In Chapter 2, we find 
that arsenic metabolism, as assessed by %iAs, %MMAs, and %DMAs, are associated with 
unique metabolomic profiles and separate diabetic and non-diabetic individuals. Finally, in 
Chapter 3 we demonstrate that genotype for AS3MT, the major protein responsible for arsenic 
metabolism is associated with a set of metabolites many of which are related to type 2 diabetes. 
These data provide mechanistic understanding, as well as inter-individual differences, for 
processes involved in diabetes development in the presence of arsenic exposure. 
A primary goal of the work in Chapter 1 was to identify arsenic exposure-associated 
metabolites in diabetic and non-diabetic individuals. This research is important as it is the first 
study to identify a profile of arsenic associated metabolites in a human population using a 
metabolomic screening method. Alterations of metabolites in response to arsenic exposure enrich 
for alterations in metabolic pathways related to energy metabolism, vitamin B metabolism and 
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amino acid metabolism. The identified pathways suggest potential roles through which 
arsenic exposure may lead to the development of diabetes in the context of arsenic exposure. It 
was also noted that a subset of metabolites was uniquely associated with U-tAs in diabetic 
individuals alone. Additionally, as many of the identified metabolites did not overlap with 
metabolites previously identified as associated with type 2 diabetes metabolomic profiles, these 
represent novel targets for study. Taken together the first study is pioneering in its use of 
metabolomics technology in arsenic exposure studies of human populations, identification of 
pathway level alterations of the metabolome in the context of arsenic exposure and the 
identification a U-tAs associated diabetes unique fingerprint.  
 A major goal of the work in Chapter 2 was to investigates the role of arsenic metabolism 
on the metabolome. This study shows that arsenical-associated metabolites are more different 
than U-tAs associated metabolites between diabetic and non-diabetic subjects. Furthermore, we 
demonstrate that arsenicals are associated with many of the same pathways identified in 
association with U-tAs-associated metabolites. Specifically, amino acid metabolism and the TCA 
cycle. Finally, we show that increased levels of %DMAs in non-diabetic individuals are 
associated with increased levels of five amino acids (leucine, isoleucine, valine, phenylalanine 
and tyrosine). Increased levels of these amino acids has been shown to be predictive of diabetes 
status in three separate cohort studies. Taken together, data from the second study demonstrate 
that arsenic metabolism plays a key role in development of arsenic-associated diabetes. 
Furthermore, it provides increased mechanistic understanding as to why increased proportions of 
%DMAs are more strongly associated with likelihood of developing diabetes than U-tAs.  
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 The research presented in Chapter 3 examines inter-individual differences as a 
susceptibility factor for diabetes development. Given that AS3MT is the key enzyme responsible 
for metabolism of arsenic, and the second study demonstrated the importance of arsenic 
metabolism on the metabolism, it is probable that genotypic differences in AS3MT is associated 
with risk of diabetes development. We set out to understand the mechanisms by which genotype 
may confer susceptibility on certain individuals. A set of 36 urinary and plasma metabolites were 
identified to be associated with allelic composition of four SNPs of AS3MT. Many of the 
metabolites were associated with diabetes development or mechanisms of diabetes development. 
Additionally, nay of the metabolites were metabolites associated with the pathways associated 
with both arsenic exposure and arsenic metabolism: energy metabolism, amino acid metabolism 
and vitamin B metabolism. Taken together, these data suggest that arsenic metabolism, 
specifically that mediated by AS3MT, is important to understanding inter-individual risk 
associated with diabetes development.  
 In conclusion, these three studies demonstrate the role of arsenic exposure, metabolism 
and susceptibility factors related to arsenic metabolism, in altering the metabolome. These data 
represent some of the first to utilize metabolomic screening in the context of arsenic exposure. 
The conclusions from these studies inform mechanistic understandings of arsenic-associated 
diabetes in human populations and potential targets for intervention in the context of arsenic 
associated DM.  
The urinary metabolic fingerprint is associated with arsenic metabolism and AS3MT 
genotype 
 In Chapter 1, an arsenic-associated diabetes unique fingerprint was identified. We 
identified a total of 59 metabolites identified in association with arsenic exposure, as assessed by 
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U-tAs, that were not found in non-diabetic individuals. Additionally, 47 of these metabolites 
were not found to be associated in metabolomic studies of traditional type 2 diabetes.  
 
Figure 7. Comparison of U-tAs (exposure) based fingerprint of arsenic-associated diabetes to 
metabolites found to be significantly associated with each of the arsenical measures in diabetic 
and non-diabetic subjects. 
 When we compare these metabolites to those identified in association with arsenical-
measures in diabetic and non-diabetic individuals identified in Chapter 2, we find that there are a 
number of overlaps (Figure 7). Surprisingly, the most overlaps (n=13) were observed in 
association with %iAs (Figure 7). This was contrary to our a priori hypothesis that the most 
overlaps would be identified in association with %DMAs, as increased levels of %DMAs are 
associated with risk of diabetes development. Among the metabolites identified in association 
with %iAs in cases were amino acid related metabolites (3.4-Dehydro-DL-proline, serine), and 
TCA related metabolites (succinate).  Only two metabolites, hexanedioic acid and theritol were 
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associated %MMAs in case and the fingerprint. Lastly for %DMAs in diabetic individuals, there 
were four fingerprint metabolites: 3-hydroxy-3methylglutaric acid, hexanedioic acid, 3,3-
dimethylglutaric acid and 3,4-dihydro-DL-proline. All of the DMA metabolites were associated 
in a direction opposite to the association of U-tAs. These metabolites may provide increased 
information about relationships between arsenic exposure, alterations in arsenic metabolism and 
diabetes risk.  
Interestingly, we found some of the metabolites in our fingerprint were associated with 
arsenicals in non-diabetic individuals. Interestingly among these there was a strong overlap 
between those associated with %iAs and %DMAs (Figure 7). There were five fingerprint 
metabolites shared between the %iAs and %DMAs: Isohomovanillic acid, 5-methylcytosine, 
gluconic acid, 3,4-Dehydro-DL-proline and ribofuranose. 3,4-Dehdyro-DL-proline was also 
associated with %MMAs. Tyrosine was associated with %DMAs and %MMAs. There was one 
metabolite, 5-methylcrotonylglycine, uniquely associated with %iAs. Similarly, there was one 
metabolite, deoxycorticosterone, uniquely associated with %DMAs. Again, %DMA associations 
of metabolites tended to be in the opposite direction of the U-tAs association. The metabolites 
associated with arsenicals in non-diabetics could be related to metabolic processes related to the 
development of diabetes making them potential targets of interest for study in understanding how 
arsenic exposure leads to diabetes development.  
Lastly, we compared the metabolomic fingerprint metabolites to those identified in 
association with AS3MT genotype in Chapter 3. We identified three of the fingerprint metabolites 
that were associated with one SNP in AS3MT. These were 5-aminolevulinic acid, which was 
associated with rs3740390 in the overall model. Oxalic acid was identified in association with 
rs17881215 in diabetic individuals alone. 11-eicosenoic acid was identified in association with 
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rs11191439 and rs17881215 in non-diabetic individuals alone. These metabolites may be related 
to risk of diabetes development thus playing a role in inter-individual susceptibility.  
The comparison of the identified metabolites to those identified as an arsenic exposure-
associated diabetes fingerprint reveals that arsenic metabolism and genotype of AS3MT may be 
related to development of arsenic-associated diabetes. If these things were unrelated we would 
expect that there would be no overlaps between the metabolite sets. The presence of these 
overlaps suggests that these metabolites may be targets for further study in understanding the 
relationship between arsenic exposure, metabolism and risk of diabetes development.  
Arsenic metabolism and genotype for AS3MT are linked to alterations related to 
mechanism of arsenic-associated diabetes 
 Given that arsenic metabolism has been linked to disease outcomes, and that AS3MT 
genotype has been linked to development of arsenic metabolism, overlaps between metabolic 
profiles associated with arsenicals and AS3MT genotypes were of interest. Interestingly, we 
observed overlaps between the profiles. Among non-diabetic individuals, only the plasma 
metabolite 2,5-dihydroxybenzoic acid overlapped between arsenical profiles and allelic variation 
of SNP rs3740390 in non-diabetic individuals (Figure 8). It is a result of metabolism of acetyl 
salicylic acid (aspirin).  Interestingly, increased production of this metabolite is associated with 
increased stress on the oxidative-stress response system and has been proposed as an early 
biomarker of oxidative stress in diabetic individuals [169]. It has also been shown that 
production of this plasma metabolite is higher in diabetic rats than non-diabetic rats and may be 
associated with diabetes-related complications[168]. We observed a decrease of this metabolite 
in association with increasing %iAs in non-diabetic individuals exposed to arsenic, as well as an 
increase in the 2,5-dihydroxybenzoic acid in relationship to the presence of the variant allele for 
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the SNP rs3740390. These data suggest that metabolism in carriers of the variant allele could be 
associated be experienced increased oxidative stress. Additionally, it also suggests that higher 
levels of %iAs may be an indicator of lower oxidative stress. 
 
Figure 8. Comparison of metabolites associated with allelic variation in one of six AS3MT 
SNPs and arsenical profiles. 
 Also among non-diabetic individuals we observed decreased levels of the metabolites 
2,3-diaminopropanoic acid and choline in association with %DMAs (Figure 8). Increased levels 
of these metabolites were associated with the presence of the variant alleles for SNP rs17881215 
in diabetic individuals. At present there is little knowledge regarding the role of 2,3-
diaminopropanoic acid in human health. However, choline is a methyl donor and essential 
nutrient in humans. Choline is involved in regulation of homocysteine concentrations. This is 
directly relevant to arsenic metabolism as homocysteine plays a key role in the regulation of the 
second methylation step that converts MMAs to DMAs. Furthermore, choline deficiency 
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attenuates insulin resistance and glucose intolerance in mice. Additionally, choline induces 
glucose and insulin resistance through increase glucagon action, i.e. promotion of 
gluconeogenesis. This suggests that arsenic-associated diabetes could be a combination of insulin 
resistance through increase gluconeogenesis.  Individuals carrying the variant allele of rs1788125 
could be predisposed to lower choline utilization efficiency, thus making them more likely to 
develop a diabetes phenotype.  
 Among diabetic individuals, we observed overlap between three metabolites associated 
with %iAs, and genotypic variation (Figure 8). The plasma metabolite 11-eicosenoic acid was 
associated with genotypic variation in the overall model in non-diabetic individuals. It was also 
associated with %iAs in diabetic individuals. This metabolite is a long chain unsaturated acid. 
Interestingly, it has been shown that incubation of insulin-producing cells with 11-eicosenoic 
acid is protective against lipotoxicity induced by fatty acids, specifically palmitin which was 
associated with genotype in diabetic individuals. This suggests that perhaps that individuals who 
carrier the variant allele for rs17881215 or rs.11191453 have higher levels of 11-eiconsenoic 
acid making their pancreatic beta cells less susceptible to toxicity. Additionally, as arsenic is 
associated with decreased lipid storage capacity of LT3 cells, it is possible that increased 11-
eiconsenoic acid acts as a protective mechanism against arsenic induced lipotoxicity in the 
pancreas.  
 A total of five metabolites were associated with %MMAs and genotypic variation in both 
the diabetic individuals (Figure 8). These metabolites were: 5-hydroxydopamine, 3-
desoxypentitol, 3-methylglutaric acid, phenylacetylglycine, and quinolinic acid. Interestingly 
quinolinic acid was decreased in association with increasing proportions of DMAs. Higher levels 
of 3-methylglutaric acid, phenylacetylglycine, and quinolinic acid have all be observed at higher 
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levels in healthy subjects as compared to their diabetic counterparts. In addition, quinolinic acid, 
a product of tryptophan metabolism, has been shown to directly inhibit phosphoenolpyruvate 
carboxykinase, resulting in hyperglycemia in rats. Given their association with increased 
%MMAs and variant alleles for SNPs previously associated with increased proportions of 
MMAs in urine it is possible that individuals are predisposed to generating increased levels of 
the metabolites and that arsenic metabolism increases these metabolites. These data suggest that 
there is perturbation of phenylalanine and tryptophan metabolism in response to arsenic 
metabolism resulting in increased susceptibility to diabetes. These metabolites represent a key 
area of focus for future research as they are likely important in the development of diabetes in 
the context of arsenic exposure.  
Arsenic exposure, metabolism, and inter-individual differences are related to arsenic- 
associated diabetes through a series of metabolic pathways 
The effects of arsenic exposure are dependent on metabolism of arsenic which is related 
to genotype of AS3MT (Figure 9). The metabolism of arsenic results in alterations of enzymatic 
process throughout the body (Figure 9). Both the metabolism of arsenic as well as the alterations 
of other enzymatic processes are directly related to β-cell dysfunction and alterations in insulin 
signaling processes that result in hyperglycemia (Figure 9).  
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Figure 9. Integrative schematic describing the relationship between arsenic exposure, genotype 
of AS3MT, metabolism that lead to dysfunctional phenotypes of diabetes. 
This research demonstrates that some of the processes that are either altered in response 
to arsenic exposure or in response to diabetes developed in the presence of arsenic are traditional 
diabetic processes. This is evidenced by alterations in metabolites that have been previously 
related to diabetes development in response to arsenic exposure and arsenic metabolism. These 
include the five branch chain amino acids that have been used as predictive biomarkers for 
diabetes. Given that these were observed as altered in response to arsenic exposure and arsenic 
metabolism, it is likely that arsenic works through traditional pathways for induction of diabetes. 
Additionally, alterations of the TCA cycle were observed consistently in both diabetic and non-
diabetic individuals. Given the key role of the TCA cycle in the production of ATP and it’s use 
of glucose, it seems likely that arsenic induces alterations in the TCA cycle that are perpetuated 
in the diabetic condition. Lastly, alterations in vitamin B metabolism were observed in response 
to arsenic exposure and metabolism. Given that vitamin B metabolism has been previously 
observed in response to diabetes and have been observed to attenuate arsenic-related disease 
previously, Vitamin B, specifically riboflavin, supplementation could represent a candidate for 
intervention studies. Taken together these data suggest that arsenic alters processes altered in 
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traditional diabetes and some of these processes could provide targets for intervention-based 
strategies to prevent diabetes development or prevent diabetic complications.  
Additionally, the results of these studies provide evidence that arsenic-associated diabetes 
is also related to non-traditional pathways of diabetes development. This is clearly evidenced by 
the 59 metabolites related to U-tAs in diabetic individuals the majority of these metabolites 
n=47, 80% these metabolites have not been observed in other metabolomic studies of diabetic 
individuals. Furthermore, the research presented here suggests that a subset of these metabolites 
are related to alterations in arsenic metabolism and genotype. Some of these metabolites could 
provide insights into inter-individual susceptibility to diabetes development in the presence of 
arsenic exposure. They can also provide information on targets of arsenic toxicity as well as the 
role of metabolism in arsenic, associated disease. Taken together, these 47 metabolites provide 
novel targets for understanding the development of arsenic-associated diabetes.   
Importantly, the collected studies provide evidence for mechanisms by which arsenic 
could potentially induce diabetes. The identification of quinolonic acid provides further support 
for the relationship between arsenic induction of gluconeogenesis. Additionally, 11-eiconsenoic 
acid and plamitin suggest lipotoxicity may be a mechanism by which arsenic is able to suppress 
insulin secretion and induce pancreatic β-cell apoptosis. 2,5- dihydroxybenzoic acid suggest the 
that oxidative stress response to arsenic likely plays a role in the development of diabetes. Lastly, 
the relationship between choline, arsenic metabolism and AS3MT genotype suggests a 
mechanism by which %DMAs are related to diabetes. Increased proportions of choline are linked 
to decreased proportions of homocysteine, and decreased proportions of homocysteine are linked 
to increased proportions of %DMAs. Increased choline levels are link associated with insulin 
resistance and induction of gluconeogenesis. These effects could provide a portion of the 
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explanation for the relationship between high %DMAs and development of diabetes. These data 
suggest that many of the metabolites identified could help provide mechanistic understanding of 
the relationship between arsenic exposure and diabetes.  
Taken together these data provide insight into traditional diabetes processes altered by 
arsenic exposure, suggest that some processes related to diabetes development in the context of 
arsenic exposure are unique to the condition and that metabolomics can provide a tool for 
identifying mechanistic pathways by which arsenic, arsenic metabolism and genotype relate to 
susceptibility to diabetes development. Additionally, these collected provide strong support for 
the use of metabolomics as an important tool for mechanistic understanding in humans.  
Public Health Relevance 
 Globally, more than 200 million people are exposed to inorganic arsenic at levels that far 
exceed the EPA and WHO standard.  Our research examining the relationship between 
metabolomic profiles of diabetic and non-diabetic individuals exposed to arsenic reveals 
potential mechanisms by which arsenic may induce diabetes in humans. Importantly, it also 
reveals the relationship between arsenic, metabolic pathways including vitamin B metabolism, 
amino acid metabolism and energy metabolism, and diabetes development. These pathways, 
particularly riboflavin related pathways, serve as potential targets for population-based 
intervention strategies. Nutrient supplementation of arsenic-exposed populations has shown 
success previously in mitigating disease development and our research points towards potential 
pathways of interest that might be relevant to prevention of diabetes development. Additionally, 
our findings demonstrate that arsenic may alter pathways traditionally altered in type 2 diabetes 
making some of the newly developed biomarkers, specifically the five branched chain and 
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aromatic amino acids, effective for early identification of susceptibility individuals. Lastly, we 
demonstrate the potential mechanistic relationship for a gene by environment by disease 
interaction. Specifically, we show that genotypes of AS3MT are related to metabolites that are 
known to be altered in diabetes. A set of these metabolites are also altered in response to arsenic 
exposure and arsenic metabolism. These findings can help our understanding of inter-individual 
difference which in turn allows for better protections of susceptible populations. Furthermore, 
this research is directly relevant to human subjects and can serve as a model for future human 
population based mechanistic work. We have effectively utilized an untargeted metabolomic 
profiling approach to identify metabolites altered in association with arsenic-related and disease-
related processes. Additionally, this work was conducted in readily obtainable bio specimens, 
demonstrating the broad applicability of metabolomics to many fields of studies. The results 
demonstrate that the integration of metabolomic data with other data types, such as existing 
information of toxicant metabolism, and genotypic data is a viable technique for understanding 
mechanisms of disease development as well as underlying mechanisms of inter-individual 
susceptibility. Taken together these studies provide the basis for future hypothesis for prevention 
and treatment, adds to the existing body of literature about health effects of arsenic exposure that 
can be used for regulatory purposes, as well as demonstrate the relevance of metabolomic 
profiling in public health research.  
Relationship of Current Research to Future Hypotheses  
 Our research reveals metabolic pathways that are mechanistically associated with arsenic 
exposure and diabetes development. This is among the first studies to apply the use of 
metabolomic profiling in the context of environment-disease research. For this reason, there are 
clear areas to target to improve the mechanistic understandings and public health relevance 
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garnered from this study. Our findings provide the basis for hypothesis generation and research 
questions, include those detailed here.  
1. What enzymes are altered in association with metabolites associated with 
arsenic-associated diabetes?  
Results from our study suggest that arsenic exposure alters enzymatic activity related to 
processes involved in diabetes development. However, it is currently unknown which precise 
enzymatic processes, tissues and organ systems are responsible for the observed impacts. Given 
that urinary metabolites represent many diverse organ systems, i.e. metabolites in urine may be 
derived from the blood stream by the kidneys, they could be impacted by organ-based arsenic-
associated alterations. Identifying the target sites at which these metabolites are produced and 
which enzymes are affected is critical to understanding which processes are associated with 
arsenic-induced diabetes.  
A major strength of cell culture work is it is performed directly in the cell type of interest, 
therefore enzymes can be inhibited at to understand whether that is the controlling factor in the 
observed phenotype. However, at present cell culture cannot link multiple organ systems 
together as they would be in a complete organism. While only indirect measures of the 
metabolites are possible in human population research, one of its major strengths as the ability to 
observe the whole system working together. Working towards understanding what enzymes are 
targeted by arsenic exposure could provide insight into which organ systems are altered and thus 
provide context for the metabolic alterations that have occurred. This could help focus the field 
not those metabolites that would be crucial for development of intervention and therapeutic 
strategies. Furthermore, the understanding of arsenic’s enzymatic targets in the cell could 
provide mechanistic understanding for its multimodal effects, not just those related to diabetes. 
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The hypothesis that could be tested would be: Enzymes related to arsenic-associated diabetes 
would be those know to alter the levels of the metabolites identified in urine.  
Computational methods provide the best hope for understanding enzymatic processes tied 
to metabolomic profiles. The development of a comprehensive database of metabolites, their 
relationships to enzymatic processes and which organ systems they exist. At present these data 
have to be manually curated, however using machine learning and integrating a use interface 
could be useful. Additionally, a computational model would have the added benefit of being able 
to integrate across cell culture and human population models. As more metabolomics studies are 
conducted, the need for this type of database will get strong, and the need for this type of 
program would be invaluable to numerous researchers.  
2. What nutritional modifiers could be used for intervention in human population 
studies?  
Given the public health focus of this research it is important to think about how the 
present research could result in intervention with the goal of disease prevention. The present 
work has focused on identification of what pathways are linked to arsenic-associated diabetes. 
Among these are choline and vitamin B. In previous research it has been shown that arsenic 
metabolism can be shifted to produce more DMAs and less MMAs by supplementation with 
folate. Additionally, researchers have focused on understanding the relationship between 
numerous anti-oxidants as to prevent arsenic related disease. Finally, vitamin B has been 
associated with attenuated disease risk in the context of arsenic exposure, specifically for skin 
lesions.  Given this successful history of supplementation, understanding which pathways can be 
targeted to decrease the risk of diabetes development and testing of these trials through 
intervention based strategies could mitigate disease burdens in countries with highly exposed 
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populations. The hypothesis that could be tested would be: Riboflavin can prevent arsenic-
induced effects in cell culture, and riboflavin supplementation of an arsenic exposed population 
will decrease the number of individuals who develop diabetes.  
To make intervention possible, one would have to tests each of the four mechanisms by 
which arsenic is able to induce diabetes and the nutritional modifier. Given the results of the 
present research, riboflavin would be a good modifier to test first. One could set up cell culture 
models like those described in the introduction, to test the effects of riboflavin on (i) insulin 
resistance/signaling, (ii) pancreatic β-cell damage, (iii) pancreatic β-cell dysfunction, and (iv) 
induction of gluconeogenesis. If riboflavin was successful at preventing arsenic and its 
metabolites from inducing these effects in cell culture, animal models could be tested next and 
then it could be applied to human populations.  
3. What is the mechanistic role of AS3MT in inter-individual differences on disease 
risk?  
Given that AS3MT is the major enzyme responsible for arsenic metabolism, it is obvious 
that it would play a role in disease susceptibility related to arsenic exposure. Interestingly the 
majority of these variants are found in non-coding regions of the gene. This suggests that the 
causal linkage between genotype and the observed effects is either related to regulatory 
capacities of region.  In fact, it has been previously linked to proportions of arsenic metabolites 
in urine as well as odds of an individual being diabetic. Our work elucidates metabolites linked 
to differences in AS3MT genotype. Understanding what enzymes and processes these metabolites 
represent is crucial for understanding how AS3MT genotype influences disease susceptibility. 
The hypothesis to be tested would be: Diverse cell culture and animal models (i.e. those with 
variations in AS3MT) will display different metabolic alterations in response to arsenic exposure.  
82 
 
To better understand the relationship between AS3MT genotype and disease 
susceptibility, future research could include cell culture models and/or genetically diverse animal 
models. One experiment would be to examine the response of diverse cell lines to arsenic 
exposure to determine differences in enzymatic and metabolic alterations. The other would be to 
expose genetically diverse animal models to arsenic and use metabolomic profiling of urine and 
serum as well as target tissue assessment to understand differences in AS3MT expression and 
other enzymatic activity on disease susceptibility and progression.  
Conclusions 
In summary, a major contribution of this work is the finding of metabolomic profiles that 
differentiate arsenic-associated diabetes from traditional type II diabetes. This is demonstrated by 
the differences in metabolomic profiles related to arsenic exposure, arsenic metabolism and 
inter-individual differences related to arsenic metabolism (AS3MT genotype). Among these are 
metabolites that play critical roles in processes of energy metabolism, amino acid metabolism 
and vitamin B metabolism. Collectively, these studies increase knowledge related to the 
mechanisms by which arsenic-induces diabetes in humans, acting as a foundation for future 
toxicology and public health research.  
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APPENDIX 1 
Supplemental Table 1. Studies detailing the relationship between arsenic exposure and diabetes 
development in both highly exposed (median >150 µg iAs/Lin drinking water) and low exposure 
(median <150 µg iAs/L in drinking water). 
Study 
Design 
Location Diabetes 
Diagnosis 
Exposure 
Measure 
(mean) 
Analysis Factors Major Finding 
High Exposure 
Chen et al 
2010 (cross-
sectional) 
Bangladesh, 
HEALs 
(n=11,319) 
Self-
reported 
prior to 
baseline 
DW-iAs, 
U-tAs 
Age, sex BMI, smoking 
status, education 
adjOR=1.11 
(0.73-1.69) 
Chiu et al 
2006 
(ecological) 
Taiwan 
(n=139,051) 
Death 
Certificate 
Drinking 
Water 
Supply 
Change 
Unadjusted Females SMR= 
1.53 (p<0.01) 
Huang et al 
2014 (cross-
sectional) 
Cambodia 
(n=142) 
HbA1c, 
Blood 
glucose 
level 
DW-iAs, 
U-tAs, 
arsenicosi
s 
Unadjusted DW-iAs 
adjOR= 1.7 
(0.5-5.8), 
arsenicosis 
adjOR=1.7 
(0.5-5.6) 
Lai et al 
1994 (cross-
sectional) 
Taiwan 
(n=891) 
Self-
reported, 
OGTT, 
treatment 
history 
CEI 
(mean 
and 
range) 
Age, sex, BMI, physical 
activity 
adjOR=10.005 
(1.3-77.9) 
Nabi et al 
2005 (cross-
sectional) 
Bangladesh 
(n=235) 
Blood 
Glucose 
DW-iAs Unadjusted OR=2.95(0.954
-9.279) 
Rahman et 
al 1999 
(cross-
sectional) 
Bangladesh 
(n=1,107) 
Self-
reported, 
OGTT, 
glycosuria 
Keratosis 
vs. non-
karatosis 
Age adjPR=5.2 (2.5-
1.5) 
Rahman et 
al 1998 
(cross-
sectional) 
Bangladesh 
(n=430) 
Glycosuria DW-iAs, 
CEI 
Age, sex, BMI adjPR=2.9 (1.6-
5.2) 
Tsai et al 
1999 
(retrospecti
ve) 
Taiwan 
(n=19,563 
deaths) 
Death 
Certificate 
Endemic 
regions 
vs. 
national 
reference 
Age, sex SMR=1.46 
(1.28-1.67) 
Tseng et al 
2000a, 
2000b 
(prospectiv
e cohort) 
Taiwan 
(n=446) 
Fasting 
blood 
glucose, 
OGTT 
CEI, 
artisan 
well 
Age, sex, BMI RR=2.1 (1.1-
4.2) 
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Wang et al 
2003 (cross 
sectional) 
Taiwan 
(n=706,314) 
Insurance 
Claims 
Endemic 
vs. non-
endemic 
regions 
Age, sex adjOR=2.69 
(2.65-2.73) 
 
Low Exposures 
Brauner et 
al 2014 
(prospectiv
e cohort) 
Denmark 
(n=57,053) 
Diabetes 
discharge 
diagnosis, 
treatment 
history/pur
chases 
Time 
weighted 
arsenic 
exposure 
(calculate
d) 
adjusted for age, BMI, sex, 
waist circumference, 
smoking, environmental 
tobacco smoke, dietary 
intake, education, SES 
Adjusted 
IRR=1.03 
(1.01-1.06) 
Coronado-
Gonzales et 
al 2007 
(case 
control) 
Mexico 
(n=400) 
Fasting 
blood 
glucose, 
treatment 
history 
U-tAs 
(creatinin
e 
adjusted), 
DW-iAs 
Age, sex, hypertensions, 
family history, obesity, 
serum lipids 
adjOR=2.84 
(1.64-4.92) 
Currier et 
al 2014 
(cross-
sectional) 
Mexico 
(n=374) 
Fasting 
blood 
glucose, 
OGTT, 
self-
reported, 
use of 
medication 
exfoliated 
urothelial 
cells 
Age, sex, BMI adjOR iAs= 
1.57 (1.19-
2.07), 
MMAs=1.63 
(1.24-2.15) , 
DMAs=1.31 
(0.96-1.84) 
Del Razo et 
al. 2011 
(cross-
sectional) 
Mexico 
(n=258) 
Fasting 
blood 
glucose 
DW-iAs Age, sex, obesity, 
hypertension 
adjOR=1.13 
(1.05-1.22) per  
10 µg As/L 
D'lppoliti et 
al 2015 
(cross-
sectional) 
Italy 
(n=165,609) 
Mortality 
Registry 
Cumulati
ve arsenic 
does 
indicator 
(calculate
d) 
Age, calendar period, 
employment at ceramics 
industry 
Cox Hazard 
Ratio=2.56 in 
females 
Ettinger et 
al 2009 
(cross-
sectional) 
USA (n=456 
pregnant 
females) 
Impaired 
glucose 
tolerance 
(OGTT) 
Blood 
iAs, Hair 
iAs 
Age, pre-pregnancy BMI, 
race, medicated use, 
married/living with partner 
adjOR=2.79 
(1.13-6.87) 
Ettinger et 
al 2014 
(cross-
sectional) 
USA (n=150 
African 
decent 
young 
adults) 
Elevated 
fasting 
blood 
glucose 
(not 
diabetes) 
Blood iAs recruitment site, 
employment status, 
education, marital status, 
smoking, alcohol, fish 
intake, age, sex 
adjOR=4.1 
(1.2-14.6) 
Feng et al 
2015 (cross-
sectional) 
China 
(n=2242) 
Fasting 
plasma 
glucose 
U-tAs Age, BMI, sex, 
hypertension, 
hyperlipidemia, family 
history of diabetes, anti-
diabetes drug/insulin use 
adjOR=1.827 
(1.096-3.045) 
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Feseke et al 
2015 (cross-
sectional) 
Canada 
(n=3151) 
Blood 
glucose, 
HbA1c 
U-tAs Age, sex, educational level, 
alcohol, smoking, BMI, 
hypertension, creatinine 
Diabetes 
adjOR=1.81 
(1.12-2.95) 
Prediabetes 
adjOR= 2.04 
(1.03-4.05) 
Gribble et 
al 2012 
(cross-
sectional) 
USA 
(n=3924) 
Fasting 
plasma 
glucose, 
OGTT, 
HbA1c or 
diabetes 
medication 
Baseline 
U-tAs  
Age, sex, urinary 
creatinine, education, 
smoking alcohol, BMI 
adjOR= 1.55 
(1.39-1.73) 
Islam et al 
2012 (cross-
sectional) 
Bangladesh 
(n=1004) 
Fasting 
blood 
glucose, 
self-
reported 
CEI via 
drinking 
water 
Age, sex, education, BMI, 
family history of diabetes 
RR=1.9 (1.1-
3.5) 
James et al 
2013 
(cohort) 
USA 
(n=1096) 
Fasting 
plasma 
glucose, 
OGTT, 
self-
reported 
with 
verificatio
n  
Time-
weighted 
average in 
residential 
drinking 
water 
Race, BMI, physical 
activity 
adjOR= 1.27 
(1.01-1.59) 
Janovic et 
al 2013 
(cross-
sectional, 
ecological) 
Serbia: 
Exposed 
region 
(n=195,190) 
n vs. general 
population(n
=1,324,489) 
National 
registry of 
diabetes 
Public 
water 
supply 
system 
iAs levels 
Unadjusted OR=1.32 (1.01-
1.73) 
Kim et al 
2011 (cross-
sectional) 
South 
Korea, 
NHANES 
(n=1,677) 
Fasting 
blood 
glucose, 
self-
reported, 
or diabetes 
medication 
U-tAs, 
creatinine 
adjusted 
Age, sex, BMI, smoking, 
alcohol, education, 
hypertension, region, 
urban/rural, seafood 
consumption  
RR=1.31 (1.04-
1.66) 
Kim et al 
2013 (case-
control) 
USA 
(n=900) 
OGTT Baseline 
U-tAs 
Age, sex, BMI, creatinine 1.11 (0.7-1.57) 
Kuo et al 
2015 
(prospectiv
e cohort) 
USA 
(n=1694) 
Blood 
glucose, 
self-
reported 
diabetes 
history or 
U-tAs Sex, education, smoking 
status, alcohol, BMI, waist 
to hip ratio, urinary 
creatinine 
Higher %MMA 
is associated 
with lower risk 
of diabetes 
HR=0.84 (0.76-
0.94) 
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medication 
use 
Lee et al 
2013 (cross-
sectional) 
South 
Korea, 
NHANES 
(n=3,393) 
Blood 
glucose, 
anti-
diabetic 
medication
, self-
reported 
U-tAs Sex, age, group, residence 
location, season, 
educational level, smoking 
status, drinking status, 
BMI, physical activity, 
seafood consumption 
adjOR=1.654 
(1.03-1.518) 
Lewis et al 
1999 
(retrospecti
ve) 
USA (n=961 
male deaths, 
1242 female 
deaths) 
Death 
certificate 
DW-iAs 
(well 
water) 
Sex, race Females: 
SMR= 1.23 
(0.86-1.71) 
Males: SMR= 
0.79 (0.48-
1.22) 
Li et al 
2013 (cross-
sectional) 
China (n= 
669) 
Fasting 
plasma 
glucose, or 
use of 
diabetes 
medication 
DW-iAs Age, Sex, BMI, alcohol, 
smoking, cumulative 
arsenic exposure 
adjOR=1.58 
(0.58-4.26) 
Mahram et 
al 2013 
(ecological) 
Iran 
(n=15,069) 
Fasting 
plasma 
glucose 
Endemic 
vs. non-
endemic 
regions 
Unadjusted, stratified by 
sex 
adjOR= 1.03 
(1.02-1.04) 
Makris et 
al 2012 
(cross-
sectional) 
Cyprus 
(n=317) 
Self-
reported 
CEI 
estimated 
via 
regional 
data 
Age, sex, smoking adjOR= 
1.86(0.30-
11.59) 
Meliker et 
al 2007 
(retrospecti
ve) 
USA 
(n=41,282 
male deaths, 
n=38,722 
female 
deaths) 
Death 
certificate 
DW-iAs Sex, race Females: 
SMR= 1.28 
(1.18-1.37) 
Males: SMR= 
1.27 (1.19-
1.35) 
Mendez et 
al 2016 
(cross-
sectional) 
Mexico 
(n=1,160) 
Blood 
glucose 
levels 
DW-iAs, 
U-tAs 
Age, sex, education, 
ethnicity, smoking, 
alcohol, waist 
circumference, BMI, 
primary source of drinking 
water, seafood intake 
DW-iAs 
adjOR= 1.65 
(0.97-2.81), U-
tAs 
adjOR=1.99 
(1.19-3.33) 
Navas-
Acien et al 
2008 (cross-
sectional) 
USA, 
NHANES 
(n=788) 
Fasting 
blood 
glucose, 
self-
reported, 
medication 
U-tAs Sex, age, race, creatinine, 
education, BMI, serum 
cotinine, hypertension 
medication, urine arseno-
betaine, blood mercury 
adjOR=3.58 
(1.18-10.83) 
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Navas-
Acien et al 
2009 (cross-
sectional) 
USA, 
NHANES 
(n=1279) 
Fasting 
blood 
glucose, 
self-
reported, 
medication 
U-tAs Sex, age, race, creatinine, 
education, BMI, serum 
cotinine, hypertension 
medication, blood mercury 
adjOR=2.60 
(1.12-6.03) 
Pan et al 
2013 (cross-
sectional) 
Bangladesh 
(n=957) 
HbA1c DW-iAs, 
toenail 
arsenic 
Cigarette smoke, BMI, age, 
sex, status of skin lesions 
adjOR=4.51 
(2.01-10.09) 
Peng et al 
2015 
(retrospecti
ve case 
control) 
China 
(n=431) 
Antenatal 
care 
records 
U-tAs Newborn sex, maternal 
age, pre-pregnancy BMI, 
gravidity and parity 
adjOR= 5.25 
(1.99-13.86) 
(1st vs. 4th) 
Peng et al 
2015 (cross-
sectional) 
USA, 
NHANES 
(n=835) 
Fasting 
glucose, 
insulin 
U-tAs, 
iAs, 
DMAs 
creatinine, 
sociodemographic factors, 
BMI, waist circumference, 
arseno-betaine 
adjOR= 0.25% 
(0.23- 0.29) 
associated with 
HOMA-IR 
Rhee et al 
2013 (cross-
sectional) 
South 
Korea, 
NHANES 
(n=3,602) 
Fasting 
blood 
glucose, 
Serum 
insulin 
U-tAs, 
creatinine 
adjusted 
BMI, physical activity, 
educational status 
adjOR=1.56 
(1.03-2.36) 
Ruiz 
Navarro et 
al 1998 
(case-
control) 
Spain (n=87 
hospital 
patients) 
Not 
reported 
U-tAs Unadjusted RR=0.87 (0.5-
1.53) 
Shapiro et 
al 2015 
(cross-
sectional) 
Canada 
(n=1274 
pregnant 
women) 
Impaired 
glucose 
tolerance 
and 
gestational 
diabetes in 
chart 
U-tAs Age, race, pre-pregnancy 
BMI, education 
adjOR= 3.7 
(1.4-9.6) 
Steinmaus 
et al 2009a 
(cross-
sectional) 
USA, 
NHANES 
(n=795) 
Fasting 
blood 
glucose, 
self-
reported, 
medication 
U-tAs Sex, age, race, creatinine, 
education, BMI, serum 
cotinine, hypertension 
medication, blood mercury 
adjOR=1.15 
(0.53-2.50) 
Steinmaus 
et al 2009b 
(cross-
sectional) 
USA, 
NHANES 
(n=1280) 
Fasting 
blood 
glucose, 
self-
reported, 
medication 
U-tAs  Sex, age, race, creatinine, 
education, BMI, serum 
cotinine, hypertension 
medication 
adjOR=1.03 
(0.38-2.80) 
Tollestrup 
et al 2003 
USA 
(n=1074 
deaths) 
Death 
certificate 
Residence 
time 
within an 
Unadjusted RR=1.6 (0.36-
7.16) 
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(retrospecti
ve) 
arsenic 
area 
Wang et al 
2007 (cross-
sectional) 
Taiwan 
(n=660) 
Metabolic 
Syndrome 
(Fasting 
Plasma 
Glucose) 
High vs. 
low iAs in 
hair 
Age, sex, occupation, 
lifestyle factors 
adjOR=2.53 
(1.02-5.43) 
Wang et al 
2009 (cross-
sectional) 
China 
(n=235) 
Hospital 
records, 
exam 
DW-iAs Unadjusted RR=1.098 
(0.98-1.231) 
Ward and 
Pim 1984 
(cross-
sectional) 
UK (n=117 
diabetes 
clinic 
patients) 
Not 
Reported 
Blood iAs Unadjusted RR=1.09 (0.79-
1.49) 
Zierold et 
al 2004 
(cross-
sectional) 
USA 
(n=1185 
well water 
testing 
participants) 
Self-
reported 
DW-iAs Age, sex, BMI, smoking adjOR=1.02 
(0.49-2.15) 
*OR=odds ratio 
*adjOR=adjusted odds ratio 
*PR=prevalence ratio 
*RR=relative risk 
DW-iAs= drinking water inorganic arsenic 
U-tAs= Urinary total arsenic (sum of iAs, MMAs, DMAs) 
IRR=incidence risk ratio 
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APPENDIX 2  
Supplemental Table 2. Metabolites identified with altered levels (either positive or negative) 
associated with U-tAs in either urine (U) or plasma (P) in diabetic (D) or non-diabetic (ND) 
individuals and their respective beta values. 
HMDB Metabolite Urine Plasma Urine ND Urine D Plasma 
ND 
Plasma D Comparis
on to 
previous 
studies 
HMDB
02453 
(R*,R*)-2,3-
Dihydroxybut
anoic acid 
 (-) PD    -0.221502  
HMDB
01961 
1,7-
Dimethylguan
osine 
(+) 
UD 
  0.208906    
HMDB
10351 
11-beta-
hydroxyandr
osterone-3-
glucuronide 
(+) 
UND, 
UD 
 0.254513 0.232284    
HMDB
02231 
11-Eicosenoic 
acid 
 (+) PD    0.207193  
HMDB
10338 
11-Oxo-
androsterone 
glucuronide 
(+) 
UD 
  0.325399    
HMDB
03099 
1-Methyluric 
acid 
(+) 
UND 
 0.238989     
HMDB
00370 
2-Amino-3-
phosphonopr
opionic acid 
(-) 
UND, 
UD 
 -0.399353 -0.397866    
HMDB
00337 
2-
Deoxytetronic 
acid 
 (+) PD    0.225864  
- 2-
furanylmetha
nol 
(-) 
UND, 
UD 
 -0.32544 -0.279091    
HMDB
00317 
2-Hydroxy-3-
methylpentan
oic acid 
(+) 
UD 
  0.209135    
HMDB
00321 
2-
Hydroxyadipi
c acid 
(+) 
UD 
  0.237492    
HMDB
00606 
2-
Hydroxygluta
ric acid 
(+) 
UND 
 0.283882     
HMDB
02285 
2-
Indolecarbox
ylic acid 
(+) 
UD 
  0.452335    
HMDB
00379 
2-Methylcitric 
acid 
(+) 
UND, 
UD 
 0.247932 0.347649    
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HMDB
00426 
2-
Methylmalic 
acid 
(+) 
UND 
 0.24978     
HMDB
02176 
2-
Methyloctano
ate 
(+) 
UD 
  0.205282    
- 2'-Nitro-4',5'-
dimethoxyace
tophenone 
(+) 
UND 
 0.376147     
HMDB
00392 
2-Octenoic 
acid 
(-) 
UND 
 -0.256751     
HMDB
02441 
3,3-
Dimethylglut
aric acid 
(+) 
UD 
  0.280389    
- 3,4-Dehydro-
DL-proline 
 (-) PD    -0.202722  
HMDB
00323 
3-Amino-2-
piperidone 
 (-) PD    -0.27569  
HMDB
03911 
3-
Aminoisobuta
noic acid 
(+) 
UD 
  0.23779    
HMDB
01885 
3-
Chlorotyrosin
e 
(-) 
UND, 
UD 
 -0.431965 -0.3483    
HMDB
00346 
3-
Deoxyarabino
hexonic acid 
 (+) PD    0.203775  
HMDB
00355 
3-hydroxy-3-
methylglutari
c acid 
(+) 
UD 
  0.263935   Kaur 
HMDB
01476 
3-
Hydroxyanth
ranilic acid 
(+) 
UND 
 0.215583     
HMDB
00413 
3-
Hydroxydode
canedioic acid 
(+) 
UD 
  0.363839    
HMDB
06116 
3-
Hydroxyhipp
uric acid 
 (-) PND   -0.238873   
HMDB
00496 
3-Methoxy-4-
hydroxyphen
ylglycol 
glucuronide 
(+) 
UD 
  0.345336    
HMDB
03332 
3-Methoxy-4-
Hydroxyphen
ylglycol 
sulfate 
(+) 
UD 
  0.330573    
HMDB
03771 
3-Methyl-2-
ketobutyric 
acid 
 (+) 
PND 
  0.236812   
HMDB
00459 
3-
Methylcroton
ylglycine 
(+) 
UD 
  0.36697    
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HMDB
00555 
3-methyl-
hexanedioic 
acid 
(+) 
UD 
  0.230153    
HMDB
01527 
3-
Methylthiopr
opionic acid 
 (-) PND   -0.312448   
HMDB
04813 
3-
Methyluridin
e 
(+) 
UND, 
UD 
 0.471367 0.352614    
HMDB
01867 
4-
Aminohippur
ic acid 
(-) 
UND 
 -0.23088     
HMDB
00500 
4-
Hydroxybenz
oic acid 
(-) 
UND 
 -0.241778     
HMDB
01988 
4-
Hydroxycyclo
hexylcarboxyl
ic acid 
(-) 
UD 
  -0.262586    
HMDB
02040 
4-
Methoxycinn
amic acid 
 (-) PND   -0.236579   
HMDB
00695 
4-Methyl-2-
Oxovaleric 
acid 
(-) 
UD 
  -0.201484    
HMDB
04058 
5,6-
Dihydroxyind
ole 
(-) 
UND 
 -0.212518     
HMDB
01149 
5-
Aminolevulini
c acid 
(-) 
UD 
  -0.267897    
HMDB
04185 
5-
Hydroxyindol
eacetylglycine 
(-) 
UND, 
UD 
 -0.215543 -0.213705    
HMDB
02894 
5-
Methylcytosin
e 
(+) 
UD 
  0.273109    
HMDB
00884 
5-
Methyluridin
e 
(+) 
UND, 
UD 
 0.385381 0.207552    
HMDB
00267 
5-Oxoproline (+) 
UND 
 0.261195     
HMDB
01182 
6,8-
Dihydroxypu
rine 
(-) 
UND 
 -0.323023     
HMDB
00897 
7-
Methylguanin
e 
(+) 
UND, 
UD 
 0.260051 0.219655    
HMDB
10715 
Acetamide (-) 
UND, 
UD 
 -0.296614 -0.256844    
HMDB
00532 
Acetylglycine (+) 
UD 
  0.262967    
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HMDB
01494 
Acetylphosph
ate 
(-) 
UND, 
UD 
 -0.363901 -0.395307    
HMDB
00034 
Adenine (+) 
UD 
  0.227012    
HMDB
00050 
Adenosine (+) 
UND, 
UD 
 0.230834 0.224235    
HMDB
02829 
Androsterone 
glucuronide 
(+) 
UND 
 0.19766     
HMDB
00568 
Arabitol (+) 
UND, 
UD 
 0.350478 0.242236    
HMDB
06483 
Aspartic acid (-) 
UND, 
UD 
 -0.243953 -0.337276    
HMDB
00030 
Biotin (+) 
UD 
  0.400786    
METPA
0048 
Carnitine (-) 
UD 
  -0.227683   Mihlik 
HMDB
00072 
cis-Aconitic 
acid 
(+) 
UND, 
UD 
 0.344395 0.230832    
HMDB
00904 
Citrulline  (-) PD    -0.296527 Zhou 
HMDB
00063 
Cortisol  (-) PD    -0.251697  
HMDB
00562 
Creatinine (-) 
UND 
 -0.243142     
HMDB
00058 
Cyclic AMP (+) 
UND, 
UD 
 0.242615 0.371931    
HMDB
00192 
Cystine (+) 
UND 
 0.237605     
HMDB
00450 
Delta-
Hydroxylysin
e 
(-) 
UD 
  -0.235906   Zhou 
HMDB
00016 
Deoxycorticos
terone 
(-) 
UD 
(-) PND  -0.421421 -0.322224   
HMDB
01321 
Erythrose 4-
phosphate 
 (-) PND   -0.209521   
HMDB
01786 
Ethenodeoxya
denosine 
 (+) 
PND 
  0.498351   
HMDB
02023 
Ethyladipic 
acid 
 (-) PND   -0.28906   
METPA
0178 
Ethylene 
glycol 
(-) 
UND, 
UD 
 -0.344224 -0.231918    
HMDB
00134 
Fumarate  (+) PD    0.192405  
HMDB
00107 
Galactitol (+) 
UND, 
UD 
 0.307447 0.214455    
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HMDB
00565 
Galactonic 
acid 
(+) 
UND, 
UD 
 0.253801 0.234901    
HMDB
00663 
Glucaric acid (+) 
UND 
 0.373981     
- Glucoheptose (+) 
UND 
 0.297107     
HMDB
00150 
Gluconic 
acid, lactone 
 (+) PD    0.213474  
HMDB
00620 
Glutaconic 
acid 
(+) 
UD 
  0.292332    
HMDB
00641 
Glutamine (-) 
UND 
 -0.249229     
HMDB
00661 
Glutaric acid (+) 
UD 
  0.214054    
- Gluticol (+) 
UD 
  0.204915    
HMDB
01112 
Glyceraldehy
de 3-
phosphate 
(-) 
UND 
 -0.316253     
HMDB
00131 
Glycerol (-) 
UD 
  -0.217148    
HMDB
00123 
Glycine  (+) PD    0.220799 Gall, 
Mennesa, 
Zhou, 
Zhang, 
Thalacker, 
Geidensta
m 
HMDB
00128 
Guanidineace
tic acid 
(-) 
UND 
 -0.293315     
HMDB
00448 
Hexanedioic 
acid 
(+) 
UD 
  0.272758    
HMDB
03518 
Homocitric 
acid 
(+) 
UD 
  0.278779    
HMDB
01212 
Hydantoin-5-
propionic 
acid 
 (-) PND   -0.252515   
HMDB
02434 
Hydroquinon
e 
(+) 
UND 
 0.202069     
HMDB
00115 
Hydroxyaceti
c acid 
 (-) PND   -0.221321   
HMDB
00193 
Isocitrate (+) 
UND 
 0.268509     
HMDB
00333 
Isohomovanill
ic acid 
(+) 
UD 
  0.21426    
HMDB
02092 
Itaconic acid (-) 
UND 
 -0.315275    Kaur 
HMDB
00751 
L-Threo-2-
pentulose 
 (-) PND   -0.258552   
HMDB
00182 
Lysine  (-) PD    -0.248871 Zhang 
HMDB
10382 
LysoPC(16:0)  (-) PND   -0.222764   
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HMDB
00744 
Malate (+) 
UND, 
UD 
(+) PD 0.276093 0.274521  0.229864 Manni 
HMDB
00765 
Mannitol (+) 
UND, 
UD 
 0.29004 0.299893    
HMDB
00696 
Methionine (+) 
UD 
  0.321013   Zhang 
HMDB
02108 
Methylcystein
e 
(-) 
UND, 
UD 
 -0.311451 -0.267529    
HMDB
06471 
Methylisocitri
c acid 
(+) 
UD 
  0.278779    
HMDB
01844 
Methylsuccini
c acid 
(+) 
UD 
  0.216871    
HMDB
02120 
Monoethyl 
phthalate 
 (-) PND   -0.319714   
HMDB
00812 
N-Acetyl-L-
aspartic acid 
(+) 
UND, 
UD 
 0.308397 0.213989    
HMDB
02201 
N-
Carboxyethyl
-g-
aminobutyric 
acid 
(+) 
UD 
  0.214323    
- N-
methylacetam
ide 
 (+) 
PND 
  0.356132   
HMDB
00847 
Nonanoic acid  (-) PND   -0.268792   
HMDB
02329 
Oxalic acid (-) 
UD 
  -0.220057    
HMDB
00223 
Oxaloacetic 
acid 
(-) 
UND 
 -0.334273     
HMDB
01587 
Phenylglyoxyl
ic acid 
(+) 
UD 
  0.223359    
HMDB
00205 
Phenylpyruvi
c acid 
(-) 
UND, 
UD 
 -0.316189 -0.206255    
HMDB
00272 
Phosphoserin
e 
(-) 
UND 
 -0.339303     
HMDB
00822 
p-
Hydroxyman
delic acid 
(+) 
UND 
 0.269516     
HMDB
00162 
Proline  (+) PD    0.264857 Zhou, 
Menni 
HMDB
00767 
Pseudo 
uridine 
(+) 
UND, 
UD 
 0.369608 0.243171    
HMDB
04230 
Pyrrole-2-
carboxylic 
acid 
(-) 
UND, 
UD 
 -0.351292 -0.257609    
HMDB
00508 
Ribitol (+) 
UND, 
UD 
 0.229327 0.214792    
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HMDB
01489 
Ribofuranose (+) 
UND 
(+) PD 0.360752   0.214336  
HMDB
00867 
Ribonic acid (+) 
UND 
 0.222287     
HMDB
01900 
Ribono-1,4-
lactone 
(+) 
UND, 
UD 
 0.33001 0.21305    
HMDB
00283 
Ribose (+) 
UND, 
UD 
 0.420205 0.301358    
HMDB
00187 
Serine (+) 
UD 
  0.228121    
HMDB
01266 
Sorbose (+) 
UD 
  0.233521    
HMDB
00252 
Sphingosine  (-) PD    -0.243592  
HMDB
00254 
Succinate (+) 
UD 
  0.218772   Kaur 
HMDB
00912 
Succinyladen
osine 
(+) 
UND, 
UD 
 0.283036 0.297605    
HMDB
00258 
Sucrose (+) 
UND 
 0.22199     
HMDB
00251 
Taurine (-) 
UD 
  -0.227299   Kaur, 
Zhou 
HMDB
04136 
Threitol (+) 
UD 
  0.301824    
HMDB
00925 
Trimethylami
ne N-oxide 
(-) 
UND 
 -0.266029     
HMDB
00158 
Tyrosine  (-) PD    -0.203493 Wang, 
Zhang 
HMDB
00289 
Uric acid (-) 
UND, 
UD 
 -0.350241 -0.293738   Kaur 
HMDB
00301 
Urocanic acid (-) 
UND 
 -0.251512     
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APPENDIX 3 
Supplemental Table 3. Statistically significant associations for all metabolites associated with at 
least one arsenical measure in either diabetic or non-diabetic individuals. 
  Non-Diabetic Individuals Diabetic Individuals 
Urinary 
Metabolites 
U-tAs 
Associated 
%iAs 
Associated 
%MAs 
Associated 
%DMAs 
Associated 
U-tAs 
Associated 
%iAs 
Associated 
%MAs 
Associated 
%DMAs 
Associated 
1,2-
Benzenediol 
  0.235517      
11-beta-
hydroxyandr
osterone-3-
glucuronide 
Martin et 
al 2015 
(Supp 
Table 2) 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
 0.20384  
2,3-
Diaminoprop
ionic acid 
   -0.220947     
2,3-
Dihydroxyva
leric acid 
     -0.205899   
2-
Furoylglycin
e 
     -0.212067  0.203785 
2-Hydroxy-2-
methylbutyri
c acid 
  -0.218749 0.25416     
2-
Hydroxybuty
ric acid 
  -0.280179 0.266319     
2-
Hydroxycapr
oic acid 
     0.217334 -0.221035  
2-
Indolecarbox
ylic acid 
    Martin et 
al 2015 
(Supp 
Table 2) 
0.237975   
2-
Methoxyphe
nol 
      0.253132  
2-
Methylmalic 
acid 
Martin et 
al 2015 
(Supp 
Table 2) 
     0.237801  
2'-Nitro-
4',5'-
dimethoxyac
etophenone 
Martin et 
al 2015 
(Supp 
Table 2) 
0.265042  -0.235846     
2-Octenoic 
acid 
Martin et 
al 2015 
(Supp 
Table 2) 
-0.255561       
3,3-
Dimethylglut
aric acid 
    Martin et 
al 2015 
(Supp 
Table 2) 
0.376213  -0.316575 
3,4,5-
Trihydroxyp
entanoic acid 
      0.332187  
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3-
Desoxypentit
ol 
      0.288659  
3-hydroxy-3-
methylglutar
ic acid 
    Martin et 
al 2015 
(Supp 
Table 2) 
0.22477  -0.231461 
3-
Hydroxyanth
ranilic acid 
Martin et 
al 2015 
(Supp 
Table 2) 
0.225756  -0.201986     
3-
Hydroxyphe
nylacetic acid 
  -0.23509 0.217605     
3-Methoxy-4-
hydroxyphen
ylglycol 
glucuronide 
    Martin et 
al 2015 
(Supp 
Table 2) 
0.247291   
3-Methyl-3-
hydroxybuta
noic acid 
 -0.269186  0.292451     
3-
Methylcroto
nylglycine 
 0.218632   Martin et 
al 2015 
(Supp 
Table 2) 
0.236724   
3-
Methylglutar
ic acid 
      0.234993  
3-
Pyridylacetic 
acid 
  -0.231144 0.250417     
4-(3-
Pyridyl)-3-
butenoic acid 
     0.220707   
4-
Aminohippu
ric acid 
Martin et 
al 2015 
(Supp 
Table 2) 
-0.287061  0.278682     
4-
Hydroxyphe
nylpyruvic 
acid 
      -0.21771  
5-
Hydroxydop
amine 
      0.228201  
5-
Methylcytosi
ne 
 0.21236  -0.210901 Martin et 
al 2015 
(Supp 
Table 2) 
   
5-Oxoproline Martin et 
al 2015 
(Supp 
Table 2) 
     0.234926  
7-Methyl-
indole 
     -0.209746   
Acetylphosp
hate 
Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
  0.243668 
Adenine     Martin et 
al 2015 
0.217314   
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(Supp 
Table 2) 
Alpha-
Hydroxyisob
utyric acid 
   0.213239     
Alpha-N-
Phenylacetyl-
L-glutamine 
 -0.203687       
alpha-
oxobenzenea
cetic acid 
      0.257525  
Arabitol Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
 0.292595 -0.248186 
Asparagine  -0.218912  0.213148     
Aspartic acid Martin et 
al 2015 
(Supp 
Table 2) 
 -0.260472 0.251807 Martin et 
al 2015 
(Supp 
Table 2) 
-0.225884   
Aspartyl-L-
proline 
       -0.209467 
Caproic acid  0.224522  -0.230295  -0.228942  0.23344 
Choline    -0.220947     
cis-Aconitic 
acid 
Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
0.289111  -0.215474 
Creatinine Martin et 
al 2015 
(Supp 
Table 2) 
    -0.242136   
Cysteine   -0.233847    0.208435  
Decanoylcar
nitine 
      0.296667 -0.256962 
Deoxycortico
sterone 
   -0.228152 Martin et 
al 2015 
(Supp 
Table 2) 
   
Epinephrine 
glucuronide 
      0.203595  
Fumarate        -0.209495 
Galactaric 
acid 
     0.203425   
Galacturonic 
acid 
     0.268785   
Gamma-
Glutamylcyst
eine 
 0.235754       
Glyceryl-
glycoside 
 0.236335       
Glycine      0.353263   
Guanosine   -0.25528      
Hexanedioic 
acid 
    Martin et 
al 2015 
(Supp 
Table 2) 
0.226237 0.229783 -0.288115 
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Hexanoylglyc
ine 
      0.344164  
Hydroxyphe
nylacetylglyc
ine 
 -0.25681  0.237248     
Indolelactic 
acid 
  -0.216899      
Isocitrate Martin et 
al 2015 
(Supp 
Table 2) 
      -0.207257 
Isohomovanil
lic acid 
 0.226966  -0.2173 Martin et 
al 2015 
(Supp 
Table 2) 
   
L-anthionine   -0.297686 0.21044     
L-Aspartyl-
L-
phenylalanin
e 
 -0.240737  0.263526     
Maleic acid  0.223461 0.269736 -0.319652     
Mannitol Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
0.329475   
N-Glycyl-L-
Proline 
     0.330147  -0.258 
N-Methyl-D-
aspartic acid 
      0.202348  
Norepinephri
ne sulfate 
   0.210555     
Pantothenic 
acid 
      0.229916 -0.213286 
Paraxanthine   -0.273963 0.261325     
p-Cresol   0.220543      
Phenylacetyl
glycine 
      0.258677  
p-
Hydroxyman
delic acid 
Martin et 
al 2015 
(Supp 
Table 2) 
 0.229459 -0.26346     
Proline      0.270308  -0.238382 
Pseudo 
uridine 
Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
 0.228864  
Quinolinic 
acid 
      0.27287 -0.251699 
Rhamnose      0.220647 0.252399 -0.299229 
Ribitol Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
0.311007   
Ribonic acid Martin et 
al 2015 
(Supp 
Table 2) 
     0.235562  
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Ribose Martin et 
al 2015 
(Supp 
Table 2) 
0.246473   Martin et 
al 2015 
(Supp 
Table 2) 
   
Serine     Martin et 
al 2015 
(Supp 
Table 2) 
0.313499   
Sorbose     Martin et 
al 2015 
(Supp 
Table 2) 
0.228465   
Succinate     Martin et 
al 2015 
(Supp 
Table 2) 
0.218721   
Succinylacet
one 
 -0.257808       
Threitol     Martin et 
al 2015 
(Supp 
Table 2) 
 0.249672  
Tryptophan      0.242844  -0.240216 
Tyrosine   0.219523    0.201738  
Uric acid Martin et 
al 2015 
(Supp 
Table 2) 
   Martin et 
al 2015 
(Supp 
Table 2) 
 -0.210708 0.231175 
Urocanic 
acid 
Martin et 
al 2015 
(Supp 
Table 2) 
 -0.243818      
Plasma 
Metabolites 
U-tAs 
Associated 
%iAs 
Associated 
%MAs 
Associated 
%DMAs 
Associated 
U-tAs 
Associated 
%iAs 
Associated 
%MAs 
Associated 
%DMAs 
Associated 
(R*,R*)-2,3-
Dihydroxybu
tanoic acid 
 -0.217614 -0.285698 0.32592  -0.247464   
11,14-
Eicosadienoi
c acid 
  -0.231819      
11-
Eicosenoic 
acid 
     0.233489   
1H-Indole-3-
acetamide 
 -0.276774 -0.235141 0.331153     
1-
Hydroxycycl
ohexen 
  -0.303929 0.302109     
1-
Monooleoylgl
ycerol 
      0.232453 -0.217388 
2,3,4-
Trihydroxyb
utyric acid 
      -0.247694 0.209861 
2,5-
dihydroxybe
nzoic acid 
 -0.24575       
2-Ethyl-3-
hydroxyprop
ionic acid 
     -0.284817   
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2-
furanylmeth
anol 
   0.22427     
2-Hydroxy-3-
methylbutyri
c acid 
  -0.265957 0.287551  0.290309   
2-
hydroxybuta
noic acid 
  -0.242539 0.268472     
2-
Hydroxyglut
aric acid 
     0.243172   
2-Oxo-4-
methylvaleri
c acid 
  -0.267228 0.281755     
2-
Oxoglutaric 
acid 
      -0.210545  
3,4-Dehydro-
DL-proline 
     -0.176301   
3-
Aminosalicyl
ic acid 
 -0.271217  0.279703     
3-
hydroxyanth
ranilic acid 
 -0.215782    0.239452  -0.233026 
3-
Hydroxybuty
ric acid 
      0.259151 -0.233626 
3-
Hydroxyhipp
uric acid 
 -0.221225    0.290367  -0.276859 
3-
Hydroxyvale
ric acid 
      0.214464  
3-Methyl, 3-
hydroxybuta
noic acid 
 -0.343266  0.350963     
3-methyl-2-
oxovalerate 
   0.203824     
3-
Methylthiopr
opionic acid 
Martin et 
al 2015 
(Supp 
Table 2) 
 -0.243882 0.270416     
4-
Deoxypyrido
xine 
 -0.257441    0.222566  -0.219599 
4-Methyl-2-
oxovaleric 
acid 
  -0.249396 0.276688     
6-Deoxy-
mannose 
 -0.259659  0.249709     
8-Hydroxy-7-
methylguani
ne 
   0.213461     
Alanine   -0.251836 0.291148     
Alloisoleucin
e 
 -0.269428 -0.284764      
Aminomalon
ic acid 
     0.203242  -0.233933 
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Arabitol  -0.268956  0.27191     
Arachidonic 
acid 
  -0.208688 0.235272     
Aspartic acid       -0.340247 0.235421 
Creatinine       0.23473  
Cystine        0.197624 
Dihomo-
gGamma-
Linolenic 
acid 
  -0.288582 0.29584     
Dihydrothym
ine 
     -0.224611   
Dihydrouraci
l 
 -0.228029    0.272431  -0.208977 
Ethanolamin
e 
      -0.242329  
Fructose       -0.354731  
Gluconic 
acid, lactone 
 -0.317014  0.294934     
Glucopyrano
se 
 -0.222477  0.256088     
Glucose   -0.317237 0.303442     
Hexanoic 
acid 
 -0.339242  0.323567     
Hydroxyaceti
c acid 
 -0.220953 -0.246988 0.3032   -0.229232  
Hypotaurine       -0.283522  
Hypoxanthin
e 
      -0.27749 0.247696 
Indoleacrylic 
acid 
  -0.334643 0.297617     
Isoleucine   -0.231031      
Kynurenine    0.240393     
Lanthionine      -0.268581  0.276356 
Leucine   -0.278066 0.312821     
LysoPC(16:0
) 
  -0.216071 0.358799     
Mannose  -0.210802       
Matitol       -0.271016 0.212655 
Methyl 
Phosphate 
   0.242029     
Monoethyl 
phthalate 
Martin et 
al 2015 
(Supp 
Table 2) 
    0.226049  -0.210587 
Myo-Inositol, 
phosphate 
  -0.285732 0.248448     
N-
Acetylglutam
ine 
      -0.205141  
N-formyl-
glycine 
 -0.221746  0.236345     
N-
methylleucin
e 
 -0.221787  0.256592   0.213534  
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Nonanoic 
acid 
 -0.244775       
Octanoic 
acid 
     0.243331   
Orotidine      -0.257117  0.222009 
Phenylalanin
e 
  -0.32971 0.296083     
Phosphoenol
pyruvic acid 
  -0.226821      
Phosphohydr
oxypyruvic 
acid 
     0.218277   
p-
Hydroxyphe
nylacetic acid 
      -0.226094 0.223962 
Propane-1,2-
diol 
 -0.370685  0.345704     
Pseudo 
uridine 
 -0.216404       
Ribofuranose  -0.329472  0.262901     
Succinate   -0.236397      
Taurine   -0.235806      
Threose        -0.199407 
trans-9-
Octadecenoic 
acid 
       -0.197996 
Tryptophan   -0.341143 0.303779     
Tyrosine   -0.194192 0.234835     
Uridine    0.227272     
Valine  -0.22065 -0.292817 0.332665     
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